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This Edition continues the series of earlier regular publications 
of the Department of Pharmacology, University of Tartu. First, 
it deals with the pharmacological studies of sigma, phencychdine 
and cholecystokinin receptors in the mechanism of action of 
antipsychotic, anxiolytic and cholinergic drugs. The other topic 
concerns the changes in central and peripheral benzodiazepine 
receptors during long term treatment with their ligands, and also 
the changes in calcium channels in alcohol and benzodiazepine 
abstinence. 
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THE INVOLVEMENT OF SIGMA AND 
PHENСYCLIDINE RECEPTORS IN THE 
ACTION OF ANTIPSYCHOTIC DRUGS 
Aavo Lang, Eero Vasar, 
Jaanus Harro & Andres Soosaar 
Psychopharmacology Lab, Tartu University, 
202 400 Tartu, Estonia 
The effects of acute and long-term treatment with typi­
cal neuroleptic Haloperidol, atypical antipsychotic ding clozap­
ine and selective sigma antagonist В MY 14802 were studied in 
behavioural and radioligand binding experiments. It was shown 
that halopeiidol was the most potent drug in all provided acute 
behavioural studies, reflecting "antipsychotic activity". Clozapine 
and BMY 14802 were less potent drugs to inhibit apomorphine-, 
amphetamine- and MK-801-induced behaviours in the acute ex­
periments, depending on their lower affinity for dopamine^ and 
sigma receptors compared with haloperidol. Nevertheless, cloza­
pine was a comparatively selective antagonist of apomorphine-
induced yawning and MK-801-induced motor excitation. Chronic 
treatment (for 15 days) with clozapine, differently from haloperi­
dol and BMY 14802, caused the significant increase of phencycli-
dine (PCP) receptor density in the rat forebrain and the increased 
sensitivity of rats to motor stimulating effect of PCP agonist MK-
801, indicating the probable involvement of PCP receptors in the 
action of clozapine. 
KEY WORDS: Haloperidol; Clozapine; BMY 14802; Be­
havioural effects; Radioligand binding; Dopamine receptors; Sig­
ma receptors; PCP receptors 
INTRODUCTION 
An original classification of opioid receptor, introduced by Mar­
tin et al. [13], identifies sigma receptors as the sites accounting for 
the "mania* in spinal dogs induced by N-allylnormetazocine (SKF 
10,047) and related benzomorphans. The psychotomimetic action of 
benzomorphans have since been attributed to nonopioid sites that 
are not sensitive to naloxone and etorphine [16]. In the radioligand 
binding studies the important differentiation has been made between 
2 distinct binding sites for SKF 10,047: 1) the phencyclidine (PCP) 
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site, with low affinity for SKF 10,047, is known to be related to the 
N-methyl-D-aspartate (NMDA) subtype of glutamate receptor; 2) a 
site with high affinity for SKF 10,047, which is now known as the 
sigma receptor [10; 17]. This sigma receptor exhibits high affinity 
for some neuroleptic drugs (i.e. haloperidol, chlorpromazine) [10; 
11; 19]. Several studies suggest a significant functional connection 
of PCP and sigma receptors with dopaminergic neurons. According 
to the studies of Deutch et al. [6] PCP increases dopamine release 
in mesolimbic/cortical region and decreases it in nigrostriatal struc­
tures. The prototypical sigma receptor agonist (+)SKF 10,047 has 
been shown to stimulate the activity of dopamine neurons in ventral 
tegmental area (Аде) of the rat brain [7]. Rimcazole, a selective sigma 
antagonist, effectively blocks the (+)SICF 10,047-induced excitation 
of dopamine neurons in ventral tegmental area, while having no 
effect on spontaneous firing of Ац neurons [2]. Wachtel and White 
[20] have demonstrated that the chronic administration of BMY 
14802, a selective sigma antagonist, reduces the number of sponta­
neously active Аю dopamine cells without affecting the activity of 
dopamine cells in the substantia nigra (Ag). 
The observation that benzomorphans with high affinity for the 
sigma receptor are psychotomimetics in humans has prompted the 
suggestion that the selective antagonists at the sigma receptor may 
represent a class of novel antipsychotic compounds without the ex­
trapyramidal side effects [18]. Although, Janowsky and Berger [8] 
have found, that clozapine, an atypical neuroleptic, moderately ac­
tive compound at dopamine2 receptors is rather potent at PCP sites. 
Byrd et al. [1] have demonstrated that long-term treatment with 
haloperidol significantly increases the number of PCP binding sites 
in the rat brain. Thus, for clarifying the role of dopamine2, PCP 
and sigma receptors in the action of antipsychotic drugs we studied 
the effects of acute and chronic treatment with the classical neu­
roleptic haloperidol, the atypical antipsychotic compound clozapine 
and the selective antagonist at sigma receptors BMY 14802 in the 
behavioural and radioligand binding experiments. 
MATERIALS AND METHODS 
Animals. Male albino rats, weighing 250-300 g, and male albino 
mice, weighing 25-30 g, were used in experiments. Animals were 
housed under standard laboratory conditions (temperature 20±3 
°C), with free access to food and water. 
Acute behavioural studies. 
Apomorphine-induced yawning in rats. Test was performed as 
described by Morelli et al. [15]. Haloperidol, clozapine and BMY 
14802 were injected intraperitoneally 30 min before the administra-
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tion of apomorphine. Number of yawns was counted during lh after 
the treatment with apomorphine (0.1 mg/kg, s.c.). The commercial 
solution of haloperidol (Gedeon Richter, Hungary) was diluted in 
the saline, BMY 14802 (Bristol-Myers, USA) was dissolved in the 
saline and clozapine (Sandoz, Switzerland) was made soluble in the 
saline with the help of 1-2 drops of Tween-85 (Ferak, Germany). 
Apomorphine-induced climbing in mice was studied according 
to the method of Moore and Axton [14]: apomorphine (3 mg/kg, 
s.c.) and test compounds were injected respectively 5 min and 30 
min prior to the placement of animals into the individual wire net 
cages, where the climbing activity was registered during 30 min. 
Amphetamine- and MK-801-induced motor excitation in mice 
was measurgd in individual cylindrical cages, (040 cm) with 2 photo­
cells located in the wall. Locomotor activity was counted between 15 
and 45 min after administration of amphetamine (7.5 mg/kg, s.c.) or 
MK-801 ((+)-5-methyl-10,1 l-dihydro-5-H-dibenzo[a,d] cycloheptan-
5,10-imine maleate) (0.25 mg/kg, i.p.). The test compounds were 
injected 30 min before the measurement of motor activity. 
The ED5O values for all drugs were calculated from the dose-
response curves. 
Apomorphine-induced stereotyped behaviour in rats. Apomor­
phine (0.5 mg/kg, s.c.) was injected 30 min and the test drugs 60 
min prior to the registration of stereotyped behaviour according to 
the scale of Costall and Naylor [5]. The stereotyped behaviour was 
measured simultaneously with aggressive behaviour. 
Apomorphine-induced aggressiveness in rats was studied in the 
grouped animals (8 rats in the test cage). The animals were sensitized 
previously to apomorphine aggressiveness by 3-weeks chronic treat­
ment with apomorphine (1 mg/kg daily, s.c.). The number of rats 
showing apomorphine (0.5 mg/kg, s.c.) induced aggressive behaviour 
was registered. Haloperidol, clozapine and BMY 14802 were admin­
istered 30 min before the treatment with apomorphine. In the case of 
apomorphine-induced stereotyped behaviour and aggressiveness the 
dose of drugs, inducing complete antagonism with the behavioural 
effects of apomorphine, was registered. 
Behavioural studies after chronic treatment. Haloperidol (0.5 
mg/kg daily, i.p.), clozapine (10.0 mg/kg daily, i.p.) and BMY 14802 
(10.0 mg/kg daily, i.p.) were administered for 15 days. 48 h after 
the last injection of the test drug the MK-801-mduced behaviour 
was investigated. MK-801 (0.2 mg/kg) was administered s.c. 30 
min priorto the estimating of stereotyped behaviour according to 
the scale of Costall and Naylor [5]. After that the animals were 
placed into the open field (1 x 1 x 0.4 m). The number of crossed 
lines and rearings during 5 min was counted. The intensity of 
ataxia was measured according to the method of Contreras et al. 
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[4]. Apomorphine-induced behaviour was investigated also 48 h 
after the last injection of haloperidol, clozapine and BMY 14802. 
Apomorphine (0.15 mg/kg) was injected s.c. 15>min prior to the 
experiment. The stereotypy, number of crossed lines, rearings and 
head-dippings were estimated. 
Binding studies. For binding studies the animals were killed by 
decapitation 48 h after the last injection of the drugs. The brains 
were rapidly removed from the skull and the brain structures were 
dissected on the ice. The brain structures were stored at -20°C 
until the following procedures. Brain tissues were thawed on the 
day of experiment. Pooled tissues from 4 animals were used in all 
radioligand experiments. Tissues were homogenized with a Potter-
S homogenizer in 20 vol ice-cold 50 mM Tris-HCl buffer (pH 7.4 
or 7.7 in the case of [3H]spiperone, [3H]haloperidol or [3H]TCP, 
respectively). Membranes were washed twice by centrifugation at 
48000 x g for 15 min. After the last centrifugation the tissues were 
suspended in the incubation buffer for the appropriate binding assay. 
The radioligand binding studies were repeated at least three times. 
pHlspiperone (109 Ci/mmol, Amersham, final concentrations 
0.06-2 nM) was incubated 30 min at 37°C with the membrane 
preparation (1 mg wet weight/tube) in the 0.5 ml of incubation 
buffer consisting of Tris-HCl 50 mM, NaCl 120 mM, KCl 5 mM, 
CaCl2 2 mM, MgCl2 1 mM (pH 7.4). The nonspecific binding was 
determined in the presence of 500 nM raclopride. The reaction was 
stopped by the rapid centrifugation at 11000 x g for 4 min. 
PHjhaloperidol binding. Homogenates (12 mg wet weight/tube) 
were incubated with increasing concentrations (2.5-80 nM) of 
[3H]haloperidol (8.9 Ci/mmol, NEN) in the absence and presence 
of 10 /jM haloperidol to define specific binding. Raclopride (500 
nM) was added to each tube to block [3H]haloperidol binding to 
dopamine2 receptors. Incubation was carried out at room temperar 
ture in the total volume of 1 ml 50 mM Ttis-HCl buffer (pH 7.7). 
After a 90-min incubation at room temperature membrane-bound 
[3H]haloperidol was separated from free radioligand by rapid fil­
tration through Whatman GF/B glass fibre filters which were pre-
soaked with 0.05% polyethyleneimine. After filtration , the filters 
were washed twice (4.5 ml each) with the incubation buffer. 
PCP receptors were detected on the membranes using 7.5 nM 
[3H]TCP (60 Ci/mmol, NEN) in the presence of 2-100 nM of MK-
801. The incubation of brain membranes (12 mg wet weight/tube) 
was carried out in the total volume of 0.5 ml 5 mM Tris-HCl buffer 
(pH 8.1 at 20° C) for 45 min at room temperature. The incubation 
was terminated by rapid filtration as described above. 
The mean apparent equilibrium dissociation constants (Kj) and 
maximum number of binding sites (Bm0x) were calculated from 
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binding studies performed 48 hours after the last injection of the 
test drugs using nonlinear iterative computer curve-fitting program 
(Enzfitter) of Leatherbarrow [12]. 
The IC50 values for haloperidol, clozapine and BMY 14802 
were detected using methods described above. The concentrations of 
[3H]spiperone, [3H]haloperidol and [3H]TCP used in displacement 
experiments were 0.1 nM, 1.7 nM and 2 nM respectively. 10-12 
concentrations of test drugs were used to inhibit [3H]ligand binding. 
The experiments were repeated at least 4 times. The IC50 values 
were determined by log-plot analysis. 
RESULTS 
As shown in table 1, the studied drugs inhibited drug-induced 
behaviour in the following order of the potency: haloperidol > 
clozapine > BMY 14802. Clozapine and BMY 14802, different­
ly from haloperidol, were unable to inhibit apomorphine-induced 
stereotypies in rats. BMY 14802 did not block also the apomorphine-
induced aggressiveness in the rat. The ratios calculated between the 
effective doses of clozapine and BMY 14802 versus haloperidol in­
dicated the relatively higher potency of clozapine and BMY 14802 
in the inhibition of MK-801-induced motor excitation in mice and 
apomorphine-induced yawning behaviour in rats. 
In the radioligand binding studies haloperidol was the most po­
tent inhibitor of [3H]spiperone binding at dopamine2 sites, clozapine 
was a moderately potent compound and BMY 14802 had only weak 
affinity at dopamme2 receptors. In [3H] haloperidol binding studies 
at sigma sites haloperidol shared significantly higher affinity if com­
pared to BMY 14802, whereas clozapine was ineffective to inhibit 
[3H]haloperidol binding. All the studied compounds were ineffective 
to inhibit [3H]TCP binding (data are not shown). It is notewor­
thy that the ratio between IC50 values of clozapine and haloperi­
dol against [3H]spiperone in the rat striatum was very similar to 
the ratio between ED50 values of clozapine and haloperidol against 
apomorphine-induced climbing, amphetamine-induced motor excita­
tion and apomorphine-induced aggressiveness (table 1). In the case 
of comparison of BMY 14802 and haloperidol very similar relation 
was found between their IC50 values against [3H]haloperidol binding 
in the rat cerebellum and their ED50 values against apomorphine-
induced yawning, amphetamine-induced motor excitation and MK-
801-induced motor excitation (table 1). MK-801 (0.2 mg/kg) caused 
the stereotyped behaviour and ataxia in the rat, but also increased 
the motor activity of the animals. Repeated treatment (for 15 days) 
with clozapine (10 mg/kg daily) significantly potentiated the effect of 
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T a b l e  1  
The antagonism of haloperidol, clozapine 
and BMY 14802 with the behavioural effects of 
apomorphine, amphetamine and MK-801 in rodents and 
inhibition of in vitro radioligand binding by 
haloperidol, clozapine and BMY 14802 in the rat brain 
DRUG-INDUCED HALO­ CLOZA­ RATIO BMY RATIO 
BEHAVIOUR PERI­ PINE CLZ vs. 14802 BMY vs. 
DOL HAL HAL 
Apomorphine-induced 0.13 3.4 26 7.5 58 
yawning (rat) 
Apomorphine-induced 0.35 24.0 69 45.0 129 
climbing (mouse) 
Amphetamine-induced 0.37 17.0 46 30.0 81 
motor excitation (mouse) 
MK-801-induced 0.43 6.4 15 27.0 63 
motor excitation (mouse) 
Apomorphine-induced 0.67 >31 >46 >115 >172 
stereotypy (rat) 
Apomorphine-induced 0.67 31 46 >115 >172 
aggressiveness (rat) 
RADIOLIGAND BINDING 
[3H] spiperone binding 
in striatum 5.5 300 55 5100 927 
[3H] haloperidol binding 
in cerebellum 1.2 >10000 >8333 83 69 
ED50 (janol/kg) values are presented in the case of behavioural studies, only 
in the case of stereotyped behaviour and aggressiveness the doses of drugs 
which completely block the behaviour are represented. Radioligand binding 
studies results aie IC50 values in nM. 
MK-801 on motor activity of the rat (table 2). Long-term treatment 
with haloperidol and BMY 14802 had a tendency to increase the 
motor excitation induced by MK-801, but this potentiation did not 
reach the statistical level. 
Apomorphine (0.15 mg/kg) induced in the rat stereotyped be­
haviour and significantly decreased the motor activity in the saline 
treated group (table 3). The chronic pretreatment with clozapine and 
BMY 14802 evidently reversed the motor depressant effect of low 
dose of apomorphine. Long-term treatment with clozapine, differ­
ently from haloperidol and BMY 14802, also reduced the intensity 
of stereotyped behaviour in the rat. The chronic treatment with 
haloperidol also antagonized the motor depressant effect of apo­
morphine, however, this antagonistic effect of haloperidol was not 
statistically evident (table 3). 
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T a b l e  2  
The effect of chronic administration 
of haloperidol, clozapine and BMY 14802 on 
behavioural effects of apomorphine in the rat 
INTENSITY No OF No OF No OF 
TREATMENT OF STEREO­ CROSSED BEARINGS HEAD-DIPS 
TYPED BE­ LINES 
HAVIOUR 
SALINE+ 
SALINE - 27.3+4.4 13.1+2.8 3.0+0.8 
SALINE+ 
APOMORPHINE 3.0+0.1 14.3+2.5° 4.1+2.0° 1.3+0.4° 
HALOPERIDOL+ 
4.4+0.6* APOMORPHINE 2.8+0.3 21.6+3.0 4.8+3.5° 
CLOZAPINE* 
2.3+0.3 6 25.0+4.7* APOMORPHINE 8.0+2.6* 2.8+0.9 
BMY 14802+ 
4.3+1.3* APOMORPHINE 2.8+0.4 29.0+4.5* 8.8+3.4* 
0 
-p«).05 (if compared to saline+saline treated animals) 
* -p<0.05 (if compared to saline+apomorphine treated animals) Mann-
Whitney U-test 
T a b l e  3  
The effect of chronic administration of haloperidol, 
closapine and BMY 14802 on behavioural effects 
of MK-801 in the rat 
INTENSITY INTENSITY No OF No OF 
TREATMENT OF STEREO- OF CROSSED 
TYPED BE- ATAXIA LINES BEARINGS 
HAVIOUR 
SALINE+ 
SALINE - - 48+4 8.4+1.4 
SALINE+ 
MK-801 1.3+0.3 1.3+.03 97+14° 1.4+0.3' 
HALOPERIDOL* 
MK-801 1.6+0.3 1.8+0.3 118+12 2.3+0.8 
CLOZAPINE* 
MK-801 1.3+0.3 1.8+0.3 139+19* 6.0+2.7' 
BMY 14802+ 
MK-801 1.3+0.2 1.1+0.2 120+23 2.0+0.9 
0 
-p<0.05 (if compared to saline+saline treated animals) 
* -p<0.05 (if compared to saline+MK-801 treated animals) Mann-Wliituev 
U-test 
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Long-term treatment with haloperidol significantly increased the 
apparent number and reduced the affinity of [3H]spiperone binding 
sites in the striatum and mesolimbic structures (figure 1). The other 
studied compounds clozapine and BMY 14802 seemed to affect 
preferentially [3H]spiperone binding in the mesolimbic structures, 
however these changes were not statistically evident; 
Only the long-term treatment with clozapine induced the in­
crease of [3H]TCP binding in the rat brain, whereas BMY 14802 
and haloperidol were completely ineffective. In the frontal cortex the 
increase of density of PCP receptors induced by repeated adminis­
tration of clozapine was statistically evident (figure 2). 
The long-term treatment with BMY 14802, the selective sigma 
antagonist, caused the increase of density and the decrease of affinity 
of sigma receptors in the frontal cortex, but not in the cerebellum 
(figure 3). On the contrary, the chronic treatment with haloperidol 
decreased the density of sigma sites in the cerebellum (figure 3), but 
not in the frontal cortex. Long-term treatment with clozapine did not 
cause any statistically evident changes in [3H]haloperidol binding at 
sigma receptors. 
DISCUSSION 
According to the present study, haloperidol is the most potent 
drug among studied compounds in the behavioural and radioligand 
binding studies at dopamines and sigma receptors. Therefore, it is 
possible that both dopaminergic and "sigmaergic" mechanisms are 
involved in the action of haloperidol. The significance of sigma 
receptors in the modulation of amphetamine-, apomorphine- and 
MK-801-induced behavioural effects is obvious, because the selective 
sigma antagonist BMY 14802 is rather effective in most behavioural 
studies, except apomorphine-induced stereotypy and aggressiveness 
in the rat. The ratio of ED5q values of BMY 14802 and haloperidol 
against apomorphine-induced yawning, amphetamine- and MK-801-
induced motor excitation is quite similar to the ratio of their ICgo 
values at sigma receptors in the rat cerebellum. The results of long-
term treatment with BMY 14802 and haloperidol seem to support 
the idea about functional interaction between dopamine neurons and 
sigma receptors. Repeated treatment with haloperidol and BMY 
14802 caused different changes in the binding of [3H]spiperone 
and [3H] haloperidol in the rat brain, but similar changes at the 
behavioural level. After long-term treatment with haloperidol and 
BMY 14802 apomorphine (0.15 mg/kg) is not able to suppress the 
motor activity of the rat and the motor stimulant effect of MK-801 
is also somewhat increased. 
Clozapine, differently from haloperidol and BMY 14802, is rel-
12 
<m p* 
a g j>h 
• 3 - a  s a  8 » о д  
" и " И 
SS g£ 
5  l ' - а я  
т я . З п  M О у „ 
§ У м а 
Ž  f l | - ä  Ö "О 
(©nssi; бш/зэ|<хщ) хешд 
д Д <f 
• н V LJ 
пз m 
(m p* 
i. 
V) 
N 
ö 
• 11 
•% 
1 
I 
л 
И m 
§ 
M 
о 00 
•Ф 
£ 
s 
m 
I 
"1 
I-
«ё1 
в, 
'S '-S 
I* 
•з :  
in л 
— V S* 
lg 
5 = 9  
ai 
s 8 
11 
о S J v 
tu g 
H «а 
СЯ 13 
Ü -a 
M 60 
I 
(erissu 6ш/зэ|ош^) xeuug 
(m pyt 
(©nssü Сш/saioujj) хешд 
atively potent antagonist of MK-801, PCP agonist, induced motor 
excitation. Taking into consideration the finding of Janowsky and 
Berger [8] that clozapine is an effective inhibitor of [3H]MK-801 
binding at PCP-receptors, it is possible that this anti-MIC-801 effect 
is explainable by direct interaction of clozapine with PCP-sites. But 
our experiments do not confirm this finding, clozapine even in con­
centrations up to 100 /jM is not able to inhibit [3H]TCP binding. 
However, there may exist the possibility that MK-801 and TCP inter­
act with different sites at NMPA-ion channel. Long-term treatment 
with clozapine, differently from the action of haloperidol and BMY 
14802, potentiates MK-801-induced motor excitation. This phe­
nomenon is parallel with the increased number of PCP-sites in the 
rat frontal cortex after chronic administration of clozapine, i.e. a re­
peated treatment with clozapine induces the hypersensitivityed PCP 
receptors. A long-term treatment with clozapine does not significant­
ly change the density of dopamine2 receptors, but the involvement 
of dopaminej receptors in the action of clozapine is obvious. There 
is a good correlation between the ratio of IC50 values of clozap­
ine and haloperidol at dopamine2 receptors and their ED50 values 
in the behavioural experiments (apomorphine-induced climbing and 
aggressiveness, amphetamine-induced motor excitation). Clozapine is 
a relatively potent and selective antagonist of apomorphine-induced 
yawning and aggressiveness. - The apomorphine-induced yawning 
and aggressiveness are evoked by the stimulation of dopamine2 re­
ceptors [21; our unpublished data]. According to the existing data 
clozapine, differently from the typical neuroleptic drugs (haloperidol, 
chlorpromazine), selectively decreases the dopaminergic activity in 
the mesolimbic structures, without affecting the activity of nigros-
triatal system [3]. The different interaction of clozapine with the 
mesolimbic and nigrostriatal dopaminergic system seems to be the 
reason why clozapine antagonizes apomorphine aggressiveness, but 
not stereotyped behaviour. 
In conclusion, it is probable that not only dopamine2 receptors, 
but also sigma and PCP receptors are involved in the action of 
neuroleptic drugs. The selective sigma antagonists indirectly decrease 
the activity of dopamine neurons, but they do not seem to be strong 
antipsychotic drugs, because they do not antagonize apomorphine-
induced aggressiveness. Kane et al. [9] have shown that clozapine is 
an effective drug in the medication of schizophrenic patients resistant 
to conventional neuroleptic treatment. Thus, one could speculate 
that the interaction with PCP receptors has the significance in the 
beneficial clinical action of clozapine. 
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THE INTERACTION OF CCK ANTAGONISTS 
WITH THE LOCOMOTOR ACTIVITY 
IN THE ALBINO MOUSE 
Eero Vasar, Jaanus Harro, Aavo Lang, 
Anu Põld and Andres Soosaar 
Psychopharmacology Lab, Institute of General and 
Molecular Pathology, Tartu University 
The influence of CCK-A antagonist devazepide and CCK-
B/gastiin antagonist L-365,260 on the locomotor activity of mice 
were studied in different experiments. . Devazepide (1-methyl-
3-( 2indoloyl)amino-5-phenyl- 3H-1,4- benzodiazepin-2-one) and L-
365,260 (3R(+)-N-(2,3-dihydro-l-methyl-2-oso-5-phenyl-lH-l,4-
benzodiazepin-3-yl)-N'-(3-methyl-phenyl)urea) had the opposite 
effect on the spontaneous locomotor activity, caerulein- and 
apomorphine-induced hypomotility in the mouse. Devazepide 
in high doses (0.1-1 mg/kg IP) reduced the spontaneous motor 
activity, whereas L-365,260 in a high dose (1 mg/kg IP) increa­
sed the activity of mice. Devazepide (0.1-10 £tg/kg) moderately 
antagonized the sedative effect of apomorphine (0.1 mg/kg SC) 
and caerulein (25 y^g/kg SC), whereas L-365,260 (1-10 /zg/kg) 
significantly potentiated the actions of dopamine and CCK ago­
nists. Concomitant administration of caerulein (15 ^g/kg SC) and 
apomorphine (0.1 mg/kg SC) caused nearly a complete loss of 
locomotor activity in the mouse. CCK-B/gastrin agonist penta-
gastrin (250 /ig/kg SC) injected together with apomorphine (0.1 
mg/kg) also caused a very signifcant reduction of motor activity. 
Devazepide and L-365,260 (0.1-10 /Ltg/kg) were completely inef­
fective against caerulein-induced potentiation of apomorphine's 
hypomotility. Devazepide in high doses (0.1-1 mg/kg), reducing 
the spontaneous motor activity of mice, counteracted to the motor 
excitation induced by d-amphetamine (5 mg/kg IP). CCK agonist 
caerulein (100 /zg/kg SC) had a similar antiamphetamine effect. 
Devazepide (1-100 /Kg/kg) and L-365,260 (1 /ig/kg) completely 
reversed the antiamphetamine effect of caerulein. 
The results of the present study are reflecting the distinct role 
of CCK-A and CCK-B receptors in the regulation of motor activ­
ity. The opposite effect of devazepide and L-365,260 on caerulein-
and apomorphine-induced hypolocomotion is probably related to 
the antagonistic role of CCK-A and CCK-B receptor subtypes 
in the regulation of mesencephalic dopaminergic neurons. The 
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antiamphetamine effect of caeiulein is possibly linked to the stim­
ulation of CCK-A receptors in the mouse brain, whereas the 
blockade of both subtypes of the CCK-8 receptor is involved in 
the antiamphetamine effect of devazepide. 
Key words: Caerulein; CCK-A receptors; CCK-B receptors; De­
vazepide; L-365,260; Locomotor activity; Apomorphine; Am­
phetamine; Pentagastrin 
INTRODUCTION 
Dopamine coexists with cholecystokinin octapeptide (CCK-8) 
in some mesencephalic neurons, innervating mesolimbic and cortical 
regions [19]. Mesolimbic dopamine is known to have a significant 
role in the regulation of motor activity in rodents [3,5]. The systemic 
treatment with CCK agonists (CCK-8 and caerulein) in low doses 
significantly suppresses locomotor activity in rodents [33] and in 
higher doses the compounds are able to block stereotyped behaviour 
and hyperlocomotion induced by dopamine agonists [24, 31, 33]. It 
is suggested that several behavioural effects of CCK-8 and caerulein 
are generated through the peripheral mechanisms [26]. It is thought 
that the motor depressant effect of CCK-8 and the suppression of 
dopaminergic activity by large doses of CCK agonists are of pe­
ripheral origin and could be abolished by abdominal vagotomy in 
rats [7, 16]. Devazepide, the highly selective antagonist at periphe­
ral CCK (CCK-A subtype) receptors completely reversed the motor 
depression induced by CCK-8 in mice [22] and in rats [29]. Never­
theless, not all authors have been able to reproduce the finding that 
vagotomy can reverse the behavioural effects of CCK agonists in 
rodents. Moroji and Hagino [27] have demonstrated that bilateral 
subdiaphragmatic vagotomy does not prevent the behavioural ef­
fects of systemically administered caerulein in mice. The suppression 
of electrical self-stimulation by caerulein is completely insensitive to 
vagotomy in rats [10]. Altar and Boyar [1] have shown that periph­
erally injected CCK-8 interacts through CCK-B receptors (brain or 
central subtype) with the central dopaminergic mechanisms. Recent­
ly two different subtypes of the CCK receptor (CCK-A and CCK-B) 
have been shown to exist in the brain of rodents [11, 25]. The 
CCK-B subtype is ubiquitous in the brain, whereas CCK-A recep­
tors were shown to be localized in certain discrete regions of brain, 
including the area postrema, nucleus of the solitary tract and the 
interpeduncular nucleus [18, 25]. However, the recent behavioural, 
electrophysiological and homogenate radioligand binding studies [2, 
8, 14, 28] show CCK-A receptors to have a more widespread distri­
bution in the brain of mammals than suggested by the above CCK 
autoradiographic studies. 
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The aim of the present study is to analyze the role of CCK-
A and CCK-B receptors in the regulation of the motor activity of 
mice. Therefore, two highly selective CCK antagonists devazepide 
(CCK-A antagonist) [4] and L-365,260 (CCK-B/gastrin antagonist) 
[23] were used to reveal the role of CCK receptor subtypes in 
the regulation of motor activity and in the action of peripheral­
ly injected caerulein, an agonist at CCK receptors. The action of 
devazepide and L-365,260 WEIS studied on the spontaneous motor 
activity, apomorphine-induced hypolocomotion and amphetamine-
induced hyperlocomotion, and on the behavioural effects of caerulein 
(caerulein-induced hypolocomotion, potentiation of apomorphine-
induced hypomotility by caerulein, antiamphetamine effect of caeru­
lein) in mice. 
METHODS 
Animals. Male albino mice , weighing 20-25 g, were used 
throughout the study. Mice were maintained at 20±3° С with food 
and water ad lib. All the experiments were performed between 3 and 
9 p.m. 
Procedure. Spontaneous locomotor activity and hypolocomo­
tion induced by apomorphine and caerulein were studied in an 
open-field. Animals were placed singly into the centre of the open-
field area (30x30x18 cm, divided by lines into 16 equal squares) 
and observed during 3 min. The number of crossed lines, rearings 
and hole-dippings was counted. Apomorphine (a dopamine ago­
nist, 0.1 mg/kg ) and caerulein (a potent CCK-8 agonist, 15 and 
25 Mg/kg) were given subcutaneously 15 min before the experiment. 
CCK-B/gastrin agonist pentagastrin (0.1 and 0.25 mg/kg SC) was 
given, in one experiment, both alone and together with apomorphi­
ne. CCK antagonists (devazepide and L-365,260) were administered 
intraperitoneally 30 min prior to open-field test. 
Amphetamine-induced hyperlocomotion and antiamphetamine 
effect of caerulein were measured in the individual cages. The cage 
for registration of motor activity was a cylinder with an inner di­
ameter 40 cm and 2 photocells (located in walls) for detection of 
motor activity. Motor activity was counted between 15 and 45 min 
after intraperitoneal administration of d-aniphetamine (an indirect 
dopamine agonist, 5 mg/kg). CCK antagonists were given intraperi­
toneally 15 min before the injection of d-amphetamine. Caerulein 
(100 Mg/kg) was given subcutaneously 5 min after the administration 
of amphetamine. 
Drugs. The following drugs were used in the present study: 
caerulein (Bachem), d-amphetamine (Sigma), pentagastrin (Sani-
tas), apomorphine (Sigma), devazepide and L-365,260 (Merck Sharp 
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& Dohme). Caerulein, d-amphetamine and apomorphine were 
prepared in saline. Some drops of 0.001 N HCl were added 
for stabilizing the injection solution of apomorphine. Devazepi­
de (l-methyl-3-(2indoloyl)amino-5-phenyl-3H-l,4-benzodiazepin-2-
one) and L-365,260 (3R(+)-N-(2,3-dihydro-l-methyl-2-oxo-5-phenyl-
1H-1,4-benzodiazepin -3-yl)- N '-(3methyl-phenyl)urea) were made 
soluble in saline by adding 1-2 drops of Tween-85. The same 
vehicle, 1-2 drops of Tween-85 in saline, was the control injection 
for CCK antagonists. Each treatment was given in a volume of 0.1 
ml/10 g body weight. 
Statistical analysis. Results are expressed in the tables and 
figures as means ± S.E.M. The behavioural data were analyzed 
using one-way analysis of variance (ANOVA). Post hoc comparisons 
between individual groups were made by using Newman-Keuls test. 
RESULTS 
In the behavioural studies CCK antagonists (devazepide and L-
365,260) in low doses failed to affect the locomotor activity of mice in 
an open-field (figure 1), only in high doses they were able to change 
the behaviour of animals. Devazepide (0.1-1 mg/kg) appeared to 
decrease the number of crossed lines in an open-field [F(5,54)= 2.88, 
p< 0.05] (figure 1), whereas L-365,260 (^ mg/kg) had the opposite 
effect [F(5,54)= 2.52, p< 0.05]. The systemic administration of 
caerulein in moderate dose (25 Mg/kg) reduced the number of crossed 
lines [F(l,18)=4.3, p< 0.05] and head-dippings [F(l,18)=4.1, p< 0.05] 
in the open-field test (table 1). The pretreatment of animals with 
devazepide (0.1-10 Mg/kg) only moderately antagonized the effect 
of CCK agonist. However, in high dose (100 Mg/kg), devazepide 
even potentiated the effect of caerulein [F(5,54)= 2.62, p< 0.05 for 
crossings; F(5,54)= 4.08, p< 0.005] for head-dippings. L-365,260 
(1-100 Mg/kg) potentiated the sedative effect of caerulein [F(5,54)= 
3.64, p< 0.01 for crossings; F(5,54)= 3.49, p< 0.01 for rearinge; 
F(5,54)= 6.53, p<0.0001 for head-dippings] (table 1). Dopamine 
agonist apomorphine in low dose (0.1 mg/kg) reduced the motor 
activity of mice [F(l,18)= 4.82, p< 0.05 for crossings] (table 2). L-
365,260 (1-10 Mg/kg) significantly potentiated the sedative effect of 
apomorphine in the mouse [F(5,54)=3.94, p< 0.005 for crossed lines; 
F(5,54)=2.52, p<0.05 for rearings; F(5,54)=8.04, p< 0.00001 for 
head-dippings]. Devazepide (1-10 Mg/kg) only moderately reduced 
the effect of apomorphine, whereas in high doses (100 and 1000 
Mg/kg) it potentiated,to some extent, the effect of dopamine agonist 
[F(5,54)=4.68, p<0.001 for crossed lines; F(5,54)=2.83, p<0.05 for 
rearings) (table 2). Pretreatment with caerulein (15 Mg/kg) very 
significantly potentiated apomorphine-induced hypolocomotion in 
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Figure 1. THE EFFECT OF CCK-8 ANTAGONISTS ON THE 
SPONTANEOUS MOTOR ACTIVITY OF MICE IN AN OPEN-FIELD. 
L-365,260 (0.0001-1 mg/kg, i.p.) and devazepide (0.0001-1 mg/kg, i.p.) were 
administered 30 min before the experiment. The number of crossed lines 
during 3 min is presented in the figure. Each bar represents the mean ± 
S.E.M. for 10 animals. Data subjected to one-way analysis of variance and 
Newman-Keuls test. * - p< 0.05 (significantly different from vehicle treated 
animals). 
ОомШда Head-dtpplnos 
Figure 2. THE EFFECT OF PENTAGASTRIN ON APOMORP­
HINE-INDUCED HYPOLOCOMOTION. Apomorphine (0.1 mg/kg, s.c.) 
was given 15 min and pentagastrin (0.25 mg/kg, i.p.) 10 min prior to the 
open-field test. The number of crossings, rearings and head-dippings during 
3 min is presented here. Each bar represents the mean ± S.E.M. for 10 
animals. Data were subjected to one-way analysis of variance and followed 
by Newman-Keuls test. * - p< 0.05; ** - p< 0.01 (statistically evident 
difference from vehicle treated mice) 
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Figure 3. THE INTERACTION OF CCK ANTAGONISTS WITH 
AMPHETAMINE-INDUCED HYPERLOCOMOTION. CCK antagonists 
(0.001-1 mg/kg, i.p.) were given 15 min before d-amphetamine (5 mg/kg, 
i.p.), whereas d-amphetamine was injected 15 min prior to the experiment. 
The locomotor activity of mice was measured in the individual cages. The 
number of counts was registered during 30 min. Each bar represents the 
mean ± S.E.M. for 10 animals. Data were subjected to one-way analysis 
of variance and Newman-Keuls test. * - p< 0.05 (significantly different 
йот vehicle treated group); i** - p< 0.05; *** - p< 0.01 (if compared to 
vehicle+d-amphetamine). 
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Figure 4. THE INTERACTION OF CCK ANTAGONISTS WITH 
ANTIAMPHETAMINE EFFECT OF CAERULEIN. CCK antagonists 
(0.0001-1 mg/kg, i.p.) were injected 30 min, d-amphetamine (5 mg/kg, s.c.) 
15 min and caerulein (0.1 mg/kg, s.c.) 10 min before the experiment. The 
пищЬег of motor activity counts was registered in the individual cages 
during 30 min. Each bar represents the mean ± S.E.M. for 10 animals. Data 
were subjected to one-way analysis of variance and followed by Newman-
Keuls test. * - p< 0.05 (significantly different from vehicle+saline); ** -
p< 0.05 (if compared to vehicle+d-amphetamine); *** - p< 0.05; *** - p< 
0.01 (if compared to d-amphetamine+caerulein). 
T a b l e  1  
The interaction of L-365,260 and devazepide with 
hypolocomotion in the mouse 
Ciossed Reitlings Head-
Diug/dose lines dippings 
(during 3 min) 
Mean values ± S.E.M. 
Vehicle 77±6.2 29±6.3 22±2.9 
Vehicle + 56±5.6* 16±4.3 9±1.4* 
caetulein 25 Aig/kg 
Devazepide 0.1 ^ig/kg + 54±5.4* 13±4.8 16±3.3** 
caerulein 25 Mg/kg 
Devazepide 1 Mg/kg + 58±12.4 16±5.7 18±3.4** 
caerulein 25 pg/kg 
Devazepide 10 ^g/kg + 66±7.5 19±3.2 14±1.5** 
caerulein 25 jug/kg 
Devazepide 100 /Jg/kg + 38±8.0* 13±5.7 10±1.8* 
caerulein 25 jtg/kg 
L-365,260 1 Mg/kg + 35±6.8*,** 5±1.8*,** 10±1.8* 
caerulein 25 Mg/kg 
L-365,260 10 j^/kg + 41±8.5* 8±4.6* 13±2.5* 
caerulein 25 /Jg/kg 
L-365,260 100 Atg/kg + 40±10.5* 10±5.2* 8±1.6* 
caerulein 25 Mg/kg 
L-365,260 1000 Mg/kg + 56±9.4 14±4.8 1411.4** 
caerulein 25 /ig/kg 
CCK antagonists were administered 30 min and caetulein 15 min before 
the experiment. * - p< 0.05 (Newman-Keuls test after significant one-way 
ANOVA, if compared to vehicle treated mice). ** - p< 0.05 (Newman-Keuls 
test, in comparison to vehicle + caerulein treatment). 
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T a b l e  2  
The effect of devazepide and L-365,260 on 
apomorphine-induced hypolocomotion in mice 
Drug/dose 
Crossed Reaiings Head­
lines dippings 
(duting 3 min) 
Mean values ± S.E.M. 
60±8.8 
40±3.3* 
14.2±3.0 
10.3±3.0 
7.4±0.9 
7.5±1.2 
29±8.5* 5.4±1.6* 2.6±0.7*,** 
23±5.8*,** 5.7±1.5* 2.3±0.7*,*+ 
32±5.7* 7.5±2.4 2.8±0,8*,** 
36±5.6* 9.6±2,5 4.0±0.6* 
79±10.2 
45±5.6* 
22±4.8 
11±2.9 
7.9±2.6 
5.5±1.8 
55±6.6 13±2.6 5.1±1.6 
54±5.8 12±2.6 6.1±2.0 
33±10.0* 6±2.7* 2.8±0.9 
34±7.5* 8±2.3* 3.0±1.0 
Vehicle 
Vehicle + 
apomoiphine 0.1 mg/kg 
L-365,260 1 /tg/kg + 
apomoiphine 0.1 mg/kg 
L-365,260 10 pg/kg + 
apomoiphine 0.1 mg/kg 
L-365,260 100 A<g/kg + 
apomoiphine 0.1 mg/kg 
L-365,260 1000 /jg/kg + 
apomoiphine 0.1 mg/kg 
Vehicle 
Vehicle + 
apomoiphine 0.1 mg/kg 
Devazepide 1 /Jg/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 10 /tg/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 100 /<g/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 1000 /tg/kg+ 
apomoiphine 0.1 mg/kg 
CCK antagonists weie given 15 min prioi to apomoiphine, wheieas apo­
moiphine was injected 15 min before the expeiiment. * - p< 0.05 (Newman-
Keuls test, following significant one-way ANOVA, in comparison to vehicle 
tieated mice); ** - p< 0.05 (Newman-Keuls test, if compaied to velii-
cle-j-apomotphine). 
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T a b l e  3  
The effect of devazepide and L-365,260 on 
caerolein-indnced potentiation of motor depressant 
effect of apomoiphine 
Crossed Reaiings Head-
Dtug/dose lines 
(during 3 min) 
dippings 
Mean values ± S.E.M. 
Vehicle 85±8 35±5.8 9.8±2.8 
Vehicle + 62±12 24±3.2 7.2±1.3 
caetulein 15 /tg/kg 
Vehicle + 54±3* 21±2.6* 8.5±1.6 
apomoiphine 0.1 mg/kg 
Caetulein 15 /tg/kg + 15±5** 1.3±0.8** 1.9±0.6** 
apomoiphine 0.1 mg/kg 
L-365,260 0.1 /tg/kg + 20±6** 5.9±3.0** 0.8±0.3** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
L-365,260 1 /tg/kg + 13±5** 1.6*1.4** 2.6±1.1** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
L-365,260 10 /tg/kg + 10±4** 1.8±0.8** 1.8±0.7** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 0.1 /tg/kg + 13±5** 1.4±1.2** 1.6±0.7** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 1 /tg/kg + 10±5** 1.2±0.8** 1.0±0.5** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
Devazepide 10 /tg/kg 4- 21±10** 3.9±2.7** 3.0±1.3** 
caetulein 15 /tg/kg + 
apomoiphine 0.1 mg/kg 
CCK antagonists were injected 30 min, apomoiphine 15 min and caetulein 10 
min befoie the expeiiment. * - p<0.05 (Newman-Keuls test after significant 
one-way AN OVA, if compared to vehicle tieated mice); ** - p< 0.01 
(Newman-Keuls test in comparison to vehicle+apomotphine treatment), 
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the mouse [F(3,36)=38.4, p<0.000001 for crossed lines, F(3,36)=20.7, 
p<0.00001 for rearings, F(3,36)=5.01, p<0.01 for head-dippings) 
(table 3). The coadministration of apomorphine and caerulein caused 
nearly a complete loss of motor activity in mice. Several animals 
lay motioneless in the center of open-field area. Neither devazepide, 
nor L-365,260 could antagonize the effect of concomitant treatment 
with apomorphine and caerulein (table 3). Pentagastrin (100 Mg/kg) 
neither changed the motor activity of mice nor affected the sedative 
effect of apomorphine (0.1 mg/kg) (data not shown). 250 Mg/kg 
pentagastrin statistically reduced the number of crossings (figure 2). 
The coadministration of pentagastrin (250 Mg/kg) and apomorphine 
significantly suppressed the motor activity in mice, however the 
potentiation appeared less evident than in the case of caerulein 
[F(3,36)=6.98, p<0.001 for crossed lines; F(3,36)=4.12, p<0.01 for 
rearings]. 
An indirect dopamine agonist d-amphetamine (5 mg/kg) in­
creased the number of motor activity counts nearly three times (fig­
ure 3). L-365,260 in low dose increased the effect of d-amphetamine 
to some extent, whereas devazepide in high dose (1 mg/kg), sup­
pressing the spontaneous motor activity, completely antagonized the 
motor stimulation induced by d-amphetamine [F(9,86)=3.1, p<0.005 
for 30 min period], Caerulein (100 Mg/kg) also very potently reversed 
the motor excitation induced by dopamine agonist (figure 4). The 
pretreatment of mice with devazepide in wide dose range (1-100 
Mg/kg) completely blocked the antiamphetamine effect of caerulein 
[F(7,104)=9.56, p<0.000001 for 30 min period]. The administration 
of L-365,260 only in low dose (1 Mg/kg) also counteracted the an­
tiamphetamine effect of CCK agonist [F(7,104)=4.48, pCO.OOOl for 
30 min period], 
DISCUSSION 
In the behavioural studies CCK-B/gastrin antagonist L-365,260 
and CCK-A antagonist devazepide have the opposite effect on 
the spontaneous locomotor activity and on the apomorphine- and 
caerulein-induced hypolocomotion in mice. The spontaneous motor 
activity is affected only by high doses of CCK antagonists, but the 
hypolocomotion induced by CCK and dopamine agonists is chan­
ged by low doses of devazepide and L-365,260. Devazepide (0.1-1 
mg/kg) reduces the spontaneous motor activity of mice, whereas 
L-365,260 (1 mg/kg) increases this behaviour. It is very puzzling that 
CCK antagonists affect apomorphine- and caerulein-induced hypo­
locomotion a similar way. Devazepide antagonizes moderately the 
sedative effect of low dose of apomorphine and caerulein, whereas 
L-365,260 significantly potentiates the action of CCK and dopami-
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ne agonists. According to the existing data the motor suppressant 
effect of apomorphine and caerulein is thought to be related to the 
decreased activity of dopaminergic cells in the mesencephalon [30, 
33]. The behavioural effects of CCK antagonists probably reflect 
the distinct role of CCK-A and CCK-B receptors in the regula­
tion of presynaptic dopaminergic activity in the mouse brain. The 
stimulation of CCK-B receptors is increasing the dopaminergic acti­
vity, whereas the interaction of CCK agonist with CCK-A receptors 
suppresses it in the mouse brain. CCK-A receptors located in the 
nucleus of solitary tract seem to be involved in the motor depressant 
effect of CCK-8 [6, 20]. Nevertheless, it is worthy to stress that 
in the present study devazepide, differently from the investigation 
of Khosla and Crawley [22], only moderately antagonizes the mo­
tor depressant effect of apomorphine and caerulein. Hamilton et 
al. [17] have shown that devazepide only partially antagonizes the 
suppression of self-stimulation induced by caerulein in the rat. All 
these experiments support the idea that not only the CCK-A recep­
tor subtype is mediating the effect of caerulein. The concomitant 
treatment with low dose of apomorphine and CCK agonist causes 
nearly a complete loss of motor activity in the mice. The animals 
are lying motionless in the middle of the open field. Devazepide 
and L-365,260 in low doses, not affecting per se locomotor activity 
of animals, are completely ineffective against the motor depression 
induced by the simultaneous administration of caerulein and apo­
morphine. Nevertheless, according to the studies of Hommer et al. 
[21] and Crawley [9] CCK receptors potentiating dopamine-induced 
hypolocomotion and suppression of the electrical activity of dopa­
mine neurons in the rat mesencephalon are belonging to the CCK-B 
subtype. Altar and Boyar [1] have found that the antagonistic ef­
fect of CCK-8 agonists (CCK-8, desulfated CCK-8 and CCK-4) on 
amphetamine evoked dopamine release in the mouse striatum is also 
related to the CCK-B receptor subtype. The similar potentiation of 
apomorphine's effect by pentagastrin and caerulein seems to support 
the above mentioned idea that CCK-B receptors are involved in the 
suppression of dopaminergic activity in the mesencephalon. Thus, 
one could speculate that the subtype of CCK-B receptors insensitive 
to L-365,260 is existing on the mesencephalic dopaminergic neurons. 
It is quite possible that these CCK-B receptors and CCK-A recep­
tors belonging to the nucleus of the solitary tract are related to the 
motor depressant effect of caerulein in mice. 
The interaction of CCK antagonists with antiamphetamine ef­
fect of caerulein and amphetamine-induced hyperlocomotion is so­
mewhat different from their action on CCK and dopamine agonists 
elicited hypolocomotion. It is suggested that the different pharma­
cology of CCK-8 against dopamine-induced hypolocomotion and 
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hyperlocomotion is related to the involvement of distinct brain re­
gions in the development of two opposite behavioural effects of 
dopamine in the rat [8, 9]. The potentiation of dopamine-induced 
hypolocomotion is linked to the interaction of CCK-8 with dopa­
mine "autoreceptors" in the ventral tegmental area, whereas the 
potentiation of dopamine-induced hyperlocomotion is related to the 
posteromedial part of the nucleus accumbens [9]. CCK-B/gastrin 
antagonist L-365,260 does not-change significantly amphetamine-
induced hyperlocomotion, but paradoxically it reverses in the low 
dose the antiamphetamine effect of caerulein. The effect of devaze­
pide is dependent on the dose of CCK-A antagonist used. In low 
doses, interacting with CCK-A receptors, it completely antagonizes 
the antiamphetamine effect of caerulein, but in high doses, inte­
racting also with CCK-B receptors (see 12, 13), devazepide per se 
reverses the effect of d-amphetamine. The antiamphetamine effect of 
devazepide is in agreement with our previous studies where the other 
CCK antagonist proglumide (5-15 mg/kg) also blocks the effect of 
d-amphetamine (our unpublished data). According to the studies of 
Moroji and Hagino [27] antiamphetamine effect of caerulein in mice 
is completely resistant to the vagotomy. It is worthy to note that 
nearly 10 times higher doses of caerulein are required for blocking 
the amphetamine-induced hyperlocomotion as compared to the se­
dative effect of caerulein. Accordingly, it seems very probable that 
CCK-A receptors involved in the antiamphetamine effect of caeru­
lein are distinct from the CCK-A receptors related to caerulein and 
apomorphine-induced hypolocomotion. The above mentioned study 
[27] is raising the possibility that these CCK-A receptors are located 
in the mouse brain. The study by Hagino et al. [15] also supports the 
idea that it is the intracerebroventricular administration of CCK-8 
and caerulein, but not desulfated CCK-8 and CCK-4, that antagoni­
zes amphetamine caused motor excitation in the mouse. The recent 
behavioural, electrophysiological and radioligand binding studies [9, 
28, 32] have established even wider distribution of CCK-A receptors 
in the rat brain than it has been stated previously [18, 25]. The 
possible mediation of antiamphetamine effect of caerulein through 
the CCK-A receptors in the mouse brain is reflecting the substantial 
difference between CCK-A receptors in the mouse and rat brain. 
Crawley et al. [8, 9] have shown that CCK-8 by interacting with 
CCK-A receptors is facilitating dopamine-induced hyperlocomotion 
in posteromedial part of the nucleus accumbens of the rat. The 
different pharmacology of CCK-A receptors in the mouse and the 
rat brain seems to account for the interspecies differences in the 
behavioural effects of caerulein in the mouse and the rat [31]. 
In conclusion, CCK-A and CCK-B receptor subtypes seem to 
have a distinct role in the regulation of motor activity. The opposite 
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effect of devazepide and L-365,260 on caetulein- and apomorphine-
induced hypolocomotion is probably reflecting the antagonistic role 
of CCK-A and CCK-B receptor subtypes in the regulation of mes­
encephalic dopaminergic cells. The stimulation of CCK-A receptors 
seems to suppress their activity, whereas the stimulation of the 
CCK-B receptor subtype has the opposite effect. Nevertheless, an­
other CCK-B receptor subtype, completely insensitive to L-365,260, 
is possibly involved in the CCK agonist-induced potentiation of apo-
morphine's hypomotility. The antiamphetamine effect of caerulein 
seems to be linked to the stimulation of CCK-A receptors in the 
mouse brain, whereas the blockade of both subtypes of the CCK-
8 receptor is probably involved in the antiamphetamine effect of 
devazepide. 
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PILOCARPINE-INDUCED LIMBIC 
SEIZURES — AN INVOLVEMENT 
OF CCK RECEPTORS 
E. Vasar, J. Harro, A. Lang, A. Soosaar 
Psychopharmacology Lab, Tartu University 
A muscarinic agonist pilocarpine (380 mg/kg) induced in all 
injected male mice the fatal seizures. The pretreatment of mice 
with CCK-8 (25-200 pg/kg) antagonized significantly the effect 
of pilocarpine, whereas the CCK-B/gastrin agonist pentagastrin 
(CCK-5, 2500 /ig/kg) only moderately inhibited the action of 
muscarinic agonist. Devazepide (10-1000 /Ug/kg), a selective an­
tagonist at CCK-A receptors, and L-365,260 (10-1000 /ig/kg), a 
selective antagonist at CCK-B receptors, antagonized the anticon­
vulsant effect of CCK-8. However, only a high dose (1 mg/kg) 
of devazepide and L-365,260 reversed significantly the action of 
CCK-8. 
In rats the administration of pilocarpine (380 mg/kg) dec­
reased significantly the number of [3H]-pCCK-8 binding sites in 
the several forebrain structures (the frontoparietal cortex, striatum 
and hippocampus). The comparison of [3H]-pCCK-8 binding in 
the brain structures of rats with and without seizures revealed 
evidently higher decrease of CCK-8 receptors' density in animals 
experiencing seizures. In the hippocampus the difference between 
the values of responders and non-responders was statistically evi­
dent. The significant reduction of [3H]-pCCK-8 binding density in 
the rat brain during pilocarpine-induced seizures probably reflects 
the involvement of CCK-B receptors. However, the weak rever­
sal of pilocarpine-induced seizures by CCK-5, and nearly similar 
action of L-365,260 and devazepide against the anticonvulsant 
effect of CCK-8 in the mouse seems to support the involvement 
of both subtypes of the CCK-8 (CCK-A and CCK-B) receptor in 
the modulation of pilocarpine-induced limbic seizures in rodents. 
KEY WORDS: LIMBIC SEIZURES; CCK-8 RECEPTORS; 
PILOCARPINE; DEVAZEPIDE; L-365,260; CCK-8 ; MOUSE; 
RAT. 
INTRODUCTION 
An involvement of cholecystokinin octapeptide (CCK-8) in the 
regulation of seizure activity has been suggested by numerous phar­
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macological studies. Thus, systemic or intracerebral administration 
of CCK-8 and its analogue caerulein inhibits seizures with different 
genesis [6, 20, 21]. On the other hand, the unspecific CCK-8 an­
tagonist proglumide reverses the anticonvulsant effect of caerulein 
against Picrotoxin and quinolinate-induced seizures, and potentiates 
seizures induced by quinolinate, an agonist at N-methyl-D-aspartate 
receptors [19, 20]. The highest levels of CCK-8 immunoreactivity 
and receptors are found in the different limbic and cortical structures 
(piriform cortex, amygdala, hippocampus etc.) [5, 12, 17], which are 
known to be involved in the regulation of seizure activity [4, 14]. 
Limbic seizures with varied genesis have been demonstrated to cause 
nearly complete loss of CCK-8 immunoreactivity from hippocampal 
mossy fiber system [3]. The potent convulsant picrotoxin is shown 
to reduce CCK-8 immunoreactivity in the several limbic regions 
[7]. The systemic treatment with muscarinic agonist pilocarpine is 
shown to cause very typical limbic seizures in rodents [18]. Mag-
nani et al. [10, 11] have shown that the systemic treatment with 
CCK-8 and caerulein significantly affects the release of acetylcho­
line from the cerebral cortex of the rat "in vivo". Therefore, the 
ahn of present work was to establish the role of CCK-8 receptors 
in the regulation of limbic seizures induced by pilocarpine in mi­
ce and rats. CCK-8, CCK-B/gastrin agonist pentagastrin (CCK-5) 
and two selective antagonists at CCK-8 receptors L-365,260 (anta­
gonist of "brain" or CCK-B receptors) and devazepide (antagonist 
of "visceral" or CCK-A receptors) [1, 9] were used for clarifying 
this problem. Simultaneously with the behavioural experiments, the 
effect of pilocarpine-induced seizures was studied on the parameters 
of CCK-8 receptors in the different brain structures of the rat. 
MATERIALS AND METHODS 
Male albino mice (25-30 g) and male Wistar rats (250-
300 g) were used throughout the experiment. The mice we­
re placed into individual observation boxes 15 min before the 
start of experiment. After this habituation period CCK antago­
nists — L-365,260 (3R(+)-N-(2,3-dihydro-l-methyl-2-oxo-5-phenyl-
lH-l,4-benzodiazepin-3-yl)-N'-(3-methyl-phenyl)urea, CCK-B anta­
gonist, 0.01-1 mg/kg) and devazepide (formerly MK-329, CCK-A 
antagonist, 0.01-1 mg/kg) — were injected 15 niin, and CCK-8 
(25-200 £tg/kg) and pentagastrin (CCK-5, 2.5 mg/kg) 10 min prior 
to muscarinic agonist pilocarpine (380 mg/kg). Mice were obser­
ved for 60 min and the latencies of onset of tremor, and tonic 
seizures and death were registered. In the radioligand binding ex­
periments with [propionyl-3H]propionylated CCK-8 (3[H]-pCCIv8) 
scopolamine methylnitrate (an antagonist at peripheral muscarinic 
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receptors) was injected 30 min prior to saline or pilocarpine (380 
mg/kg). Two subgroups of rats — responders and non-responders to 
pilocarpine-induced limbic seizures — were selected for radioligand 
binding studies. Animals, respectively with and without seizures, 
were killed by decapitation 60 min after the administration of pi­
locarpine. The brains were removed rapidly from the skulls and 
the frontoparietal cortex, mesolimbic structures (nucleus accumbens, 
tuberculum olfactorium), piriform cortex, striata and hippocampus 
were dissected [15]. The method of Praissman et al. [16] in our 
slight modification was used for 3[H]-pCCK-8 binding studies. Satu­
ration curves were analyzed using ENŽFITTER program for IBM 
microcomputers [8]. 
RESULTS 
Systemic treatment with muscarinic agonist pilocarpine (380 
mg/kg) evoked in all injected male mice (n=39) the fatal seizures. 
The pretreatment of mice with CCK-8 (25-200 yug/kg) significant­
ly antagonized the effect of 380 mg/kg pilocarpine (figure 1). 50 
Mg/kg CCK-8 obviously reversed the effect of muscarinic agonist, 
the further increase of CCK-8 dose did not enhance the effect of 
neuropeptide. 13 mice from 39 tested survived pilocarpine-induced 
seizures after administration of 200 pg/kg CCK-8. CCK-8 antag­
onist devazepide in the high dose (1 mg/kg) evidently antagonized 
the anticonvulsant effect of CCK-8 (figure 2). CCK-B antagonist L-
365,260 also after the administration of high dose (1 mg/kg) reversed 
the anticonvulsant action of CCK-8 (figure 3). However, L-365,260 
(10-1000 £tg/kg), differently from devazepide, completely blocked the 
antagonism of CCK-8 against the pilocarpine-induced lethality. 
Pilocarpine up to 1 mM did not interact with 3[H]-pCCI<-8 
binding in the radioligand studies "in vitro". The administration 
of high dose of pilocarpine (380 mg/kg) changed the parameters of 
3H-pCCK-8 binding sites in the several forebrain structures (table). 
Pilocarpine reduced significantly the number of 3 [H]-pCCK-8 bin­
ding sites in the striatum, frontoparietal cortex and hippocampus 
(table). In the hippocampus affinity of 3H-pCCIC-8 binding sites 
was also increased after administration of pilocarpine. The compari­
son of pH]-pCCK-8 binding parameters in the animals, responding 
and non-responding to pilocarpine-induced seizures, revealed mo­
re significant changes in the brain structures of rats, experiencing 
seizures (table). In the hippocampus the difference between the va­
lues of [3H]-pCCK-8 binding in responders and non-responders was 
statistically evident (table). 
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Figure 1. The effect of CCK-8 (25-200 yug/kg) and pentagastrin (CCK-
5, 2500 /ig/kg) on pilocarpine-induced seizures in mice. CCK-8 and CCK-5 
were given 10 min prior to pilocarpine (380 mg/kg). The animals were 
observed for 60 min after the administration of pilocarpine. Significant 
differences between vehicle/pilocarpine and CCK-8 or CCK-5/pilocarpine 
treated groups were determined by Newman-Keuls test after significant 
ANOVA. F5,116= 8.71, p<0.0001 (for tremor); F5,116= 10.46, p<0.000001 
(for tonic seizures and death). * - p< 0.05; ** - p< 0.01; *** - p<0.005 (if 
compared to pilocarpine treated mice). 
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Figure 2. The effect of devazepide (10—1000 pg/kg) on the anticonvul­
sant action of CCK-8 (200 ßgfkg) against pilocarpine-induced seizures in 
mice. Devazepide was injected 15 min and CCK-8 10,min prior 4o pilo­
carpine. Significant differences between pilocarpine, CCK-8/pilocarpine and 
devazepide/CCK-8/pilocarpine treated groups were determined by Newman-
Keuls test after significant ANOVA. F4,77=2.4, p<0.05 (for tregaor), 
F4,77=2.5 (for tonic seizures and death). * - p<0.05 (if compared to pilo­
carpine treated animals); ** - p<0.05 (if compared to ССК-8/pilocaipine 
treated mice). 
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Figure 3. The effect of L-365,260 (10-.1000 MS/kg) on the anticon­
vulsant effect of CCK-8 (200 Mg/kg) against pilocarpine-induced seizures 
in mice. L-365,260 was injected 15 min and CCK-8 10 min prior to pilo­
carpine. Significant differences between pilocarpine, CCK-8/pilocarpine and 
L-365,260/CCK-8/pilocarpine treated groups were determined by Newman-
Keuls test after significant ANOVA. F4,77= 2.86, p<0.05 (for tremor); 
F4,77= 3,69, p<0.01 (for tonic seizures and death). * - p<0.05 (if com­
pared to pilocarpine treated moce); ** - p<0.05 (if compared to CCK-
8/pilocarpine treated animals). 
DISCUSSION 
The results of present study are reflecting a significant role of 
CCK-8 receptors in the modulation of epileptogenic effect of a mus­
carinic agonist- pilocarpine. CCK-8 potently antagonizes the seizures 
induced by the lethal dose of pilocarpine. One third of mice sur­
vive pilocarpine-induced seizures after pretreatment with 200 Mg/kg 
CCK-8. CCK-b/gastrin agonist pentagastrin only moderately re­
duces the convulsant action of pilocarpine. Accordingly, it seems 
probable that the peripherally injected CCK-8 affects the cholin­
ergic neurotransmission in the brain. It is suggested that several 
behavioural effects of CCK-8 and caerulein are generated through 
primarily peripheral mechanisms [13]. It is thought that the sedative 
effect of large doses of CCK-8 is of peripheral origin and could 
be abolished by abdominal vagotomy [2]. Magnani et al. [10, 11] 
have shown that CCK-8, in the doses 10 Mg/kg and higher, potently 
inhibits the release of acetylcholine from the rat cerebral cortex. This 
effect of CCK-8 is not affected by bilateral vagotomy or by the lesion 
of dopaminergic cells in the substantia nigra. The selective CCK an­
tagonists devazepide and L-365,260 reverse the anticonvulsant effect 
of CCK-8. However, it happens only after the administration of 
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Table 
The binding parameters of [3H]-pCCK-8 in the brain 
structures of responding and non-responding rats to 
pilocarpine (380 mg/kg) seizures 
Brain structures Satine Non-responders Responders 
Mesolimbic area Kd 0.42±0.02 0.40±0.03 0.50±0.15 
Вшах 
4.51±0.32 4.13±0.22 3.55±0.53 
Piriform cortex Kd 0.43±0.02 0.63±0.06 0.68±0.08 
Впвх 
6.30±0.20 5.22±0.29 5.58±0.75 
Frontoparietal Kd 0.33±0.02 0.41±0.03 0.26±0.02 
cortex 
Вцвх 
5.15±0.30 3.76±0.76 2.71±0.23a 
Striatum Kd 0.27±0.01 0.45±0.07 0.36±0.04 
Вшах 
5.23±0.28 4.25±0.19a 3.74±0.24b 
Dorsal hippo­ Kd 0.63±0.04 0.37±0.05a 0.15±0.02b,c 
campus 
Впвх 
1.87±0.17 1.18±0.28a 0.56±0.05b,c 
The brain structures of 4-5 rats have been pooled. The mean values 
± S.E.M. of 4 independent experiments are presented in table. Kj -
dissociation constant in nM; Brmv - apparent number of binding sites in 
pmoles pet gram original tissue wet weight a - p< 0.05; b - p< 0.01 
(compared to saline treated rats, Student's t-test); с - p< 0.05 (compared to 
non-responders, Student's t-test). 
very high dose (1 mg/kg) of CCK antagonists. It is noteworthy that 
the effect of L-365,260 is somewhat stronger. 
L-365,260, in wide dose range (10-1000 jug/kg), antagonize also 
the effect of CCK-8 on pilocarpine-induced lethality. Nevertheless, 
the both subtypes of CCK-8 (CCK-A and CCK-B) seem to be 
involved in the anticonvulsant effect of CCK-8. According to the 
radioligand binding studies "in vitro", pilocarpine (up to 1 mM) does 
not interact directly with CCK-8 receptors in the brain. However, the 
systemic administration of very high dose of pilocarpine (380 mg/kg) 
is reducing the density of CCK-B receptors in the frontoparietal 
cortex, striatum and hippocampus of the rat brain. The comparison 
of 3[H]-pCCK-8 binding parameters in rats, responding and non-
responding to the administration of pilocarpine with seizures, reveals 
markedly higher reduction of CCK-B receptors in animals with 
seizures. It supports the idea that CCK-B receptors are involved in 
the modulation of seizures induced by muscarinic agonist. 
. In conclusion, it is very likely that the both subtypes of CCK-B 
receptor are involved in the modulation of limbic seizures induced 
by the muscarinic agonist pilocarpine. This idea is supported by 
the findings that ССК-B/gastrin agonist pentagastrin only mod­
erately antagonized the effect of pilocarpine, the selective CCK-8 
antagonists devaz.epide and L-365,260 have nearly similar effect on 
the anticonvulsant effect of CCK-8, and during pilocarpine-induced 
10* 
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seizures the density of CCK-8 receptors is significantly reduced in 
the several brain regions. 
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In the present investigation the effect of benzodiazepine re­
ceptor inverse agonist Ro 15-4513 on potassium(55 mM)-evoked 
calcium accumulation in ethanol-intoxicated (EI) and ethanol-
withdrawn (EW) rats has been studied. Ethanol was administered 
in increasing concentrations йот 2% to 10% with drinking water 
during two months. Daily intake of ethanol at the end of chronic 
administration was 15 g/kg. Ro 15-4513 (4 mg/kg, i.p.) did not 
change the calcium influx in synaptoneurosomes of control rats. 
No changes in uptake were found 2 hrs after the last ethanol 
administration (EI rats). At 24 hrs of ethanol withdrawal calcium 
accumulation was significantly increased (P>0.05). Nifedipine (5 
mg/kg, i.p.) completely reversed an increase of calcium influx 
in EW rats. Ro 15-4513 (4 mg/kg, i.p.) did not affect calci­
um accumulation in EW-rats but significantly enhanced influx 
in EI animals. Simultaneously Ro 15-4513 induced the signs of 
withdrawal in EI rats. 
These data suggest that Ro 15-4513 may induce the signs 
of withdrawal when given during ethanol intoxication and there­
fore may be potentially dangerous in patients suffering from the 
chronic ethanol abuse. 
KEY WORDS: CHRONIC ETHANOL, Ro 15-4513, CALCI­
UM INFLUX, SYNAPTONEUROSOMES 
INTRODUCTION 
Ro 15-4513 (ethyl 8-azido-5, 6-dihydro-5-methyl-6-oxo-4H-
imidazo-[l,5-a] [1,4] benzodiazepine-3-carboxylate) has been reported 
to possess behavioural effects of benzodiazepine receptor inverse ag­
onists [2, 3, 12]. Recent studies have shown that Ro 15-4513 is 
capable of antagonizing some of the behavioural effects of ethanol 
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[2,11,12, 17]]. There were speculations concerning a possible clinical 
application of this compound as a spetcific ethanol antagonist. How­
ever, the usefulness of this compound as ethanol spetcific antagonist 
during chronic ethanol intoxication has been recently questioned 
since this compound might exacerbate the signs of withdrawal. In 
fact, the administration of Ro 15-4513 increased the incidence of 
seizures in mice or rats during 5-8 hours of ethanol withdrawal [1, 
13]. There are some questions whether the administration of Ro 
15-4513 is able to precipitate the symptoms of withdrawal during 
chronic ethanol administration or this compound is able only to ex­
acerbate the existing symptoms of spontaneous withdrawal. Previous 
studies have shown that ethanol intoxication and the development 
of the withdrawal signs were associated with the changes in dihy-
dropyridine sensitive voltage-dependent calcium channels. Dolin et 
al. [7] demonstrated that calcium channel Jfntagonist nimodipine 
protected against ethanol-withdrawal seizures and the density of di-
hydropyridine binding sites is increased during ethanol withdrawal. 
Previous reports suggested that ethanol-induced intoxication and 
sedation correlate closely with the blockade of voltage dependent 
calcium entry into presynaptic nerve terminals [10] and ethanol is 
able to inhibit the fast phase of potassium-evoked calcium uptake. 
Recent results have also shown that potassium-evoked calcium en­
try intio cortical synaptosomes of animals withdrawn from chronic 
ethanol is also increased [16]. These data suggest that alteration in 
the calcium channel functions produced by the acute and chronic 
ethanol may be involved in the behavioural signs of ethanol intox­
ication and withdrawal reactions developed upon chronic ethanol 
administration. 
Our experiments were designed to study the effect of Ro 15-4513 
on behaviour and potassium-evoked calcium uptake by the cortical 
synaptosomes isolated from the rat brain at various times following 
chronic ethanol administration. 
MATERIALS AND METHODS 
Animals. The male albino rats with initial weight 200-230 g 
were housed in groups of 8-10 animals. Animals were maintained 
on food and water ad libitum. 
Ethanol treatment. The groups of animals were given ethanol 
in the drinking water in increasing concentrations from 2% to 10% 
during two months. Daily intake of ethanol at the end of chronic 
administration was 15±1 g/kg. The food intake of the control group 
was restricted to maintain a weight gain comparable to that of 
ethanol-treated animals. At the end of ethanol administration the 
bottles containing ethanol solution were replaced by water. 
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All control and ethanol administered rats were divided into two 
groups. The first group was used in experiment I, the second droup 
- in experiment II. 
EžBgžjment Т. Animals for this experiment were taken 1.5 hours 
after ethanol withdrawal when a considerably high ethanol concen­
trations were present in their blood and were referred to as ethanol 
intoxicated animals. Animals from control and ethanol group were 
injected either vehicle or Ro 15-4513 (4 mg.kg, i.p.) and were placed 
into single observation boxes. After 15 min of habituation period 
animals were observed for the incidence of myoclonic jerks as an in­
dication of withdrawal for 30 min. After performing of behavioural 
observations animals were rapidly sacrificed by the cervical disloca­
tion and their brains were taken for the biochemical assay. 
Experiment II. Animals for this experiment were taken 24 hours 
after ethanol withdrawal and were referred to as ethanol withdrawn 
animals. These animals were also injected with either saline or Ro 
15-4513 and 45 min later were directly taken for the biochemical 
assay without behavioural testing. 
45Ca2+ uptake assay 
Membrane vesicles (microsacs) were prepared according to the 
method of Harris and Allan [9]. The tissue was homogenized by 
hand (10 strokes) in 4.5 ml of ice-cold assay buffer (millimolar): 
NaCl, 145; KCl, 5; MgCl2, 1; glucose, 10; CaCl>, 1; and 4-(2-
hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES), 10, adjust­
ed to pH=7.5 with TRIS base using a glass Teflon homogenizer. The 
homogenate was centrifuged at 900 g for 15 min. The supernatant 
was decanted, and the pellet was suspended in 8 ml of assay buffer 
and centrifuged once again. The final pellet was suspended in assay 
buffer to yield a preparation containing 5-6 mg of protein per 1 ml 
of suspension. Protein content was determined by the method of 
Lowry et al., 1951). Aliquots of microsacs (1-2 mg protein/ml) were 
preincubated in volume 900 ul in glass tubes at 0 С for 10 min, and 
at 37°C for -10 min. The uptake was initiated by adding about 100 
ul of solution containing 1 uCi of ^Ca2* and 50 tnM NaCl (resting 
uptake) or 50 mM KCl (depolarization-induzed uptake). The incu­
bation was continued for the further 5 sec and was terminated by a 
rapid filtration through GF/B filters followed by four 4 ml washings 
with ice-cold buffer containing 145 mM KCl. All experiments were 
performed in triplicates. Filters were placed into scintillation vials 
containing dioxane based scintillation cocktail and, after shaking, 
were counted in Beckman scintillation counter LS-6800. 
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STATISTICS 
Student's t-test and analysis of variance was performed for the 
evaluation of the data. 
RESULTS 
Two hours after withdrawal from chronic ethanol treatment 
when ethanol was still present in high concentrations in the blood 
there were no observable signs of spontaneous withdrawal. Ad­
ministration of Ro 15-4513 in ethanol-indoxicated animals induced 
myoclonic jerks' (Fig.l). In contrast, administration of Ro 15-4513 in 
control animals did not induce any behavioural changes (data not 
shown). 
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Figure 1. Ro 15-4513 — evoked myoclonic jerks in ethanol-indoxicated 
rats. Ro 15-4513 (4 mg/kg) was injected 2 hours after ethanol withdrawal. 
In control animals Ro 15-4513 did not induce myoclonic jerks (Data not 
shown). 
In ethanol-intoxicated animals no changes in potassiumfevoked 
45Ca2+ uptake were observed in comparison to control (Fif. 2). 
Administration of Ro 15-4513 (4 mg/kg) in ethanol-intoxicated Tats 
resulted in the significant increase of 45Ca2+ uptake (Fig. 2). In 
contrast, Ro 15-4513 did not induce any changes in control animals. 
Similarly, in vitro addition of 10 um Ro 15-4513 to the incuba­
tion medium did not induce any changes in calcium flux (data not 
shown). 24 Hours after ethanol withdrawal a significant increase 
r— P<0.05 
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in potassium-evoked 45Ca2+ uptake was observed and this increase 
was not further enhanced by the pretreatment with Ro 15-4513 (Fig 
3). 
Vehicle 0ЕШ Ro 15-4513 
Š 4.00 
2.40 
0.00 
Control Ethanol-wthdr. 
Figure 2. Effect of in vivo Ro 15-4513 (4 mg/kg) administration on 
potassium-evoked 45 Ca2"*" uptake by the cortical synaptoneurosomes of 
ethanol-indoxicated rats. 
DISCUSSION 
The results of the present study demonstrated that administra­
tion of Ro 15-4513 during chronic ethanol intoxication results in the 
appearance of behavioural signs resembling those seen in rats with 
spontaneous withdrawal. The appearance of these signs suggests 
that administration of Ro 15-4513 is capable of precipitating the 
withdrawal signs in these animals. These data contradict previous 
observations where no precipitated withdrawal was found upon the 
administration of Ro 15-4513 in ethanol-intoxicated mice [1]. The 
species differences and route of ethanol administration, however, 
might account for this discrepancy. Appearance of the withdraw­
al signs was accompained by an increase in the potassium-evoked 
45Ca2+ uptake by synaptoneurosomes upon Ro 15-4513 adminis­
tration in ethanol-intoxicated rats. Although the mechanism of Ro 
15-4513-induced increase in the calcium channel function in ethanol-
intoxicated rats is not known, one may propose that these changes 
might reflect the alteration of neuronal membranes induced by chron­
ic ethanol administration. Since primary site of action of Ro 15-4513 
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Figure 3. Effect of in vivo Ro 15-4513 (4 mg/kg) administration on 
potassium-evoked 45 Ca2"*" uptake by the coitical synaptoneurosomes of 
ethanol-indoxicated rats. * — P<0.05 (Students t-test). 
is GABA-benzodiazepine-barbiturate complex linked to the chloride 
ionophore [2] and in vitro addition of Ro 15-4513 did not affect 
calcium channel function one can propose that changes in 45Ca2+ 
flux induced by in vivo administration of Ro 15-4513 are secondary 
and probably develop in response to the alteration of chloride chan­
nel function. Recent studies have shown that in vitro addition of 
ethanol in concentrations 25-200 mM inhibited 43Ca2+ flux through 
voltage-sensitive calcium channels, which might be a consequence of 
elevation of intraneuronal calcium [5, 6, 9]. The lack of any changes 
in calcium flux in chronically ethanol-intoxicated rats found in this 
study may suggest a development of tolerance to the acute effects 
of ethanol. The data obtained from experiment II demonstrated an 
increase in potassium evoked 45Ca2+ flux 24 hours after termination 
of chronic ethanol administration. Although behavioural data found 
by others demonstrated that administration of Ro 15-4513 might 
exacerbate the behavioural signs of ethanol withdrawal (Becker and 
Anton, 1989), the administration of Ro 15-4513 in our experiments 
did not produce any further increase in calcium flux, it is not exclud­
ed that 24 hours after withdrawal a maximum increase in calcium 
flux was achieved and an additional administration of RO 15-45123 
was not able to induce any further increase. 
In conclusion, the data found in the present stydy suggest that 
Ro 15-4513 may induce the signs of withdrawal when given during 
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ethanol intoxication and therefore may be potentially dangerous in 
patients suffering from chronic ethanol abuse. 
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Withdrawal of lats from chronic ethanol treatment (liquid 
Complan diet containing 10% of ethanol) resulted in an increased 
anxiety in both social interaction and plus-maze tests; this was 
accompanied by increased aggression and tremor. Baclofen (1.25-
2.5 mg/kg) did not affect the behaviour of control animals but 
reversed the anxiogenic responses and reduced aggression and 
tremor scores in ethanol-withdrawn rats. A high dose (Š.0 mg/kg) 
of baclofen reduced locomotor activity, the time spent in social 
interaction and the percent number of entries into and time spent 
on the open arms of the plus-maze in both control and ethanol 
— withdrawn rats. Nitrendipine (25-50 mg/kg) did not influence 
either anxiety or aggression in ethanol — withdrawn rats. At 
the high dose (100 mg/kg) nitrendipine produced sedation and re­
duced the time spent in the active social interaction and locomotor 
activity in both control and ethanol — withdrawn rats. This effect 
of the high dose of nitrendipine was accompanied by the reduc­
tion of tremor scores in ethanol — withdrawn rats. The results 
of the present study indicate that baclofen might be useful in the 
treatment of alcohol induced withdrawal reactions. It is proposed 
that baclofen interacting with GABAfl receptors located on the 
presynaptic nerve endings, in contrast to nitrendipine, might in­
duce a decrease in the intraneuronal calcium concentration and 
a consequent inhibition of the release of 5-HT and GABA, that 
might partly contribute to the reversal of anxiogenic responses 
and the inhibition of tremor in ethanol — withdrawn rats. 
KEY WORDS: ETHANOL WITHDRAWAL, BACLOFEN, NI­
TRENDIPINE, ANXIETY, TREMOR, AGGRESSION. 
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INTRODUCTION 
Chronic exposure of animals or humans to ethanol results in the 
development of physical dependence that is manifested by a charac­
teristic withdrawal syndrome upon the cessation of ethanol intake. 
The withdrawal syndrome in rats is characterized by increased anx­
iety, tremor, muscle rigidity and increased seizure activity [12, 13, 
29]. Previous data have suggested that development of withdrawal 
syndrome after chronic exposure to ethanol might be explained by 
diminished GABA-ergic neurotransmission [27, 28,]. Variuos param­
eters of GABA-ergic neurotransmission axe altered during ethanol 
withdrawal including an increase in ICy of the low affinity GAB A4 
receptor sites [27], and reduced GABA concentrations in various 
regions of the brain [25]. Benzodiazepines and barbiturates are used 
as sedative drugs in the treatment of the ethanol withdrawal syn­
drome where they might compensate for the decreased GABA-ergic 
inhibition (Volicer, 1980). GABA receptors have been classified into 
GABAyi and GAB Ад subtypes according to their pharmacological 
and anatomical properties [2, 3]. Previous studies have shown that 
the GABA^-receptor agonists, GABA, muscimol and THIP injected 
intracisternally reduced the severity of audiogenic seizures but had 
not effect on tremor in ethanol-withdrawn rats [14]. Less is known 
about the effect of the САВАд receptor agonist baclofen on the 
signs of ethanol withdrawal, but in one study it slightly reduced the 
tremor in ethanol — withdrawn monkeys [äž]. 
Current evidence suggests that voltage operated calcium chan­
nels also might be involved in the development of tolerance during 
chronic ethanol administration and ethanol withdrawal syndrome 
[õž]. Calcium channel antagonists nitrendipine and PN 200-110 
prevented the development of tolerance to ataxic and the general 
anaesthetic actions of ethanol when they were given concurrently 
with ethanol [5, 6, 19]. Calcium channel antagonists nitrendipine 
and nimodipine abolished ethanol withdrawal convulsions [18] and 
inhibited apomorphine-induced aggressive reactions in ethanol with­
drawn rats [23]. However, not all behavioural effects of ethanol 
withdrawal were affected by nitrendipine administration; it was 
without effect on the anxiogenic response in ethanol-withdrawn rats 
[12]. 
Recent studies show that baclofen and фе dihydropyridines 
have some common mechanism of action. Nitrendipine at nanomo­
lar concentrations inhibits binding of [3H]baclofen to GAB Ад re­
ceptors [1]. Baclofen interacting with САВАд receptors, inhibits 
voltage dependent [Ca2+],- rise in the rat brain synaptosomes [24] 
which, probably, accounts for the observed inhibitory effect of ba­
clofen on GABA, 5-hydroxytryptamine and noradrenaline release [2, 
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17]. In the present study we compared the effects of baclofen and 
nitrendipine on the anxiogenic responses, aggression and tremor in 
ethanol-withdrawn rats. 
METHODS 
Animals. Male hooded Lister rats (Ollac, Bicester, UK) with 
initial weight 180-200 g, were housed in a room with a 13 h light: 
11 h dark cycle (lights on at 06.00 hours). Animals were housed in 
groups of five until о days before testing, when they were housed 
individually. Three days prior to behavioural testing rats were 
allocated to test partners on the basis of their weight (±25 g). 
Drugs. Baclofen (Ciba Geigy) was dissolved in warm distillated 
water, nitrendipine (Sigma) was suspended in distilled water with 2-4 
drops of Tween-20 and injected intraperitoneally (ip) in a volume of 
2 ml/kg body weight. 
Ethanol treatment. Rats were randomly allocated to the ethanol 
and control diets. All the rats received 20% w/v liquid chocolate 
Complan diet; water was freely available in a separate bottle. The 
ethanol group received absolute ethanol additions to the Complan. 
This was 3% w/v on day 1 and was increased in 1% steps over the 
next 7 days. Rats were then maintained on a diet containing 10% 
ethanol for a further 4 weeks (giving a final daily dose 15.2±0.9 
g/kg/day). The liquid diet intake of control group was restricted to 
maintain comparable weight gain to the ethanol-treated rats. 
Apparatus. The social interaction test has been described in 
detail previously [10, 11]. 
The plus-maze was made of wood and consisted of two opposite 
open arms, 50x10 cm and two opposite enclosed arms, 50x10x40 cm 
with an open roof. The arms were connected by a central square, 
10x10 cm, thus the maze formed the shape of plus sign. It was 
elevated to a height of 50 cm above the floor. 
** The holeboard is a wooden box 65x65x30 cm with four holes, 
each 6.5 cm in diameter, equally spaced on the floor. Head dipping 
was measured by infra-red cells located immediately beneath the 
edges of the holes; locomotor activity and rearing were measured by 
the number of times infrared beams located in the walls of box, 4.5 
and 12.5 cm respectively from the floor, were broken. 
Behavioural procedure. The Complan diet containing ethanol 
was replaced by equivalent amount of Complan without ethanol 7.5 
h before testing. All behavioural tests were performed between 7 a.m. 
and 12 a.m. In the first experiment animals from both the control 
and the chronic ethanol diet received intraperitoneal (ip) injections 
of either vehicle or baclofen (1.25, 2.5 or 5.0 mg/kg, n=8-10/group) 
30 min before the start of testing. The animals were then given 
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behavioural tests in the following order: social interaction test, plus-
maze test and holeboard test. After testing, the rats were maintained 
on their previous ethanol or control liquid diets for a further 7 
days. They were subsequently withdrawn again from their diets for 
another 7.5 h and received i.p. either saline or nitrendipine (25, 50 
or 100 mg/kg) 30 min before testing. The animals were retested in 
social interaction test and plus-maze. 
Social interaction test. The low light, familiar test condition 
was used, thus the rats were familarized witb the test arena for 
7.5 min on the 2 days prior to testing. The behaviour of rats was 
videorecorded to permit rescoring. Two categories of behaviour 
were scored separately: active social interaction (sniffing, following, 
grooming) and aggression (fighting, aggressive posture). Locomotor 
activity was measured by breaking of photobeams positioned 4.5 cm 
above the floor. At the end of each trial test arena was thoroughly 
cleaned. 
Plus-maze test. Each rat was placed in the centre of the plus-
maze, facing an enclosed arm. An observer who was blind to the 
drug treatment, scored the number of entries into open arms and 
the number into enclosed arms and times spent on the open and the 
enclosed arms of plus-maze. Each test lasted 5 min, and at the end 
of each trial the maze was thoroughly cleaned. 
Holeboard test. Rats naive to the holeboard apparatus were 
placed singly in the centre of the holeboard and the following mea­
sures were taken during a 5 min trial: number of head dips, time 
spent head dipping, locomotor activity and rearing. At the end of 
each trial, any faecal boluses were removed and the box was wiped 
clean. 
Ethanol withdrawal-induced tremor was evaluated using the 
method of Frye et al. [14]. Tremor scores were determined by 
lifting rats vertically by the tail and scoring the following reactions: 
a score of three was assigned to rats showing an immediate forelimb 
extension and violent generalized forelimb-whole body tremor; a 
score of two was assigned to rats that showed this reaction when 
they were rotated 180o around the axis of the tail; and .core of one 
to rats that failed to display forelimb extension but showed clearly 
distinct forelimb tremor when lifted by the tail and rotated ISOo. 
The rats were scored on two occasions, once immediately before and 
once after the social interaction test; a mean of these two scores was 
taken for the statistical analysis. 
Statistical analysis. The data obtained in the behavioural exper­
iments with the excepton of tremor data were assessed with analysis 
of variance (ANOVA) followed, where appropriate, with Duncan's 
multiple range test. The data of tremor scores were analysed using 
Kruskall-Wallis H test. 
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RESULTS 
Experiment 1. Effect of ethanol withdrawal. Withdrawal from 
chronic ethanol treatment resulted in an increase of anxiety indicated 
by a reduction of time spent in active social interaction [F(l,9)=9.8, 
P<0.01], see Figure 1. An increasing anxiogenic response in social 
interaction test was accompanied by an increased score for the time 
spent in aggressive behaviours [F(l,22)=22.7 P<0.001], see Figure 2. 
Anxiogenic withdrawal response could also be detected in the plus-
maze test. Thus, the rats withdrawn from chronic ethanol treatment 
showed a decrease in % number of entries into open arms of the 
plus maze [F(l,20)=6.1, P<0.05] and the % time spent on the open 
arms [F(l,20)=10.5, P<0.01] of the plus-maze but did not change the 
total number of entries in plus-maze (Figure 3). Withdrawal from 
chronic ethanol treatment increased rearing [F(1,1S)=4.3, P<0.05], 
but did not affect other behavioural measures in the holeboard (Table 
1). Withdrawal from ethanol induced strong tremor [PcO.OOl], see 
Figure 4. 
T a b l e  1  
Effect of baclofen on locomotor activity in holeboard 
of control (CO) and chronic ethanol-withdrawn (EW) rats. 
The data are mean value ± SEM 
Behavioural measure Vehicle Baclofen (mg/kg) 
1.25 2.5 5.0 
Time spent head-dipping CON 27.8+5.0 27.7+5.7 21.8+2.7 2.0+0.6* 
EW 30.4+7.7 25.4+2.8 17.6+3.7 0.6+0.2** 
Number of head-dips CON 28.7+4.2 26.2+3.0 23.4+4.7 1.5+0.3* 
EW 33.9+6.9 28.8+4.3 24.5+6.9 0.5+0.2** 
Locomotor activity CON 427+162 465+173 338+87 61+21* 
EW 532+114 614+186 418+141 6+2** 
Rearing CON 14.6+2.9 11.3+3.1 7.7+1.2 1.0+0.5* 
EW 28.2+5.3* 33.3+8.7 19.2+4.3 0.5+0.2** 
* - Significantly differed from vehicle control, (P<0.05); ** - significantly 
differed from ethanol withdrawn rats (P<0.01) 
Effect of baclofen. Baclofen (1.25-2.5 mg/kg) did not change the 
behaviour of control animals. In ethanol-withdrawn rats baclofen 
(1.25 mg/kg) increased the time spent in active social interaction 
(Figure 1). There was a significant withdrawal x baclofen (1.25 
mg/kg) interaction [F(l,13)=20.4, P<0.01]. This effect of baclofen 
disappeared at a dose of 2.5 mg/kg, and at a dose 5 mg/kg baclofen 
decreased the time spent in social interaction in ethanol-withdrawn 
animals (Figure 1). Baclofen dose dependency inhibited aggressive 
reactions in ethanol-withdrawn rats (Figure 2). 
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Control Alcohol withdrawal 
* - P<0.05 
** - P<0.01 
Ш 
Veh. 1.25 2.5 
Baclofen 
5.0 Veh. 1.25 2.5 
Baclofen 
5.0 legAg) 
Figure 1. The time spent in social interaction by control and ethanol 
withdrawn rats 30 min after treatment with baclofen. Scores are means ± 
SEM. n = 5 per group. + - P<0.05 as compared to control group; * -
P<0.05; ** - P<0.01 as compared to vehicle treated group. 
Veh. 1.25 2.5 
B a c l o f e n  
5.0 fag/kgl 
Figure 2. Effect of baclofen on aggression in ethanol withdrawn rats. 
Scores are means ± SEM. n = 5 per group. ++ - P<0.01 as compared ю 
control group; * - P<0.05; ** - P<0.01 as compared to vehicle group. 
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Control Ethanol withdrawal 
S 30 
Veh. 1.25 2.5 5.0 
Baclofen 
Veh. 1.25 2.5 5.0 (mg/kg) 
Baclofen 
Control Ethanol withdrawal 
в 10. 
Veh. 1.25 2.5 5.0 
Baclofen 
Veh. 1.25 2.5 5.0 (mg/kg) 
Baclofen 
Figure 3. Mean (±SEM) percentage of number of entries into open 
arms (A), percentage of time spent into the open aims (B) and total number 
of entries (C) on the open and closed aims of the plus-maze by control and 
ethanol-withdrawn rats 30 min after administration of baclofen, n = 8-12 
per group. + - P<0.05 as compared to control group; * - P<0.05; ** -
P<0.01 as compared to vehicle group. (P<0.05). 
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Control Ethanol withdrawal 
§ 
S 
Veh. 1.25 2.5 5.0 
B a c l o f e n  I m g / k g l  
Control Ethanol withdrawal 
«< 
25 50 100 
n i t r e n d i p i n e  ( * g / k g )  
Figure 4. Effect of baclofen and nitrendipine on tremor in 
ethanol withdrawn rats. Scores are mean values ± SEM. n = 6-12 
per group. ++ - P<0.01 as compared to control group; ** - P<0.01 
as compared to ethanol-withdrawn group. 
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The reversal of anxiogenic response by baclofen in ethanol — 
withdrawn rats could be also detected in plus-maze test. Thus, at 
dose of 2.5 mg/kg baclofen increased % number of entries into, 
and at doses 1.25-2.5 mg/kg — % time spent on the open arms of 
plus-maze (Figure 3). The total number of entries on the plus-maze 
was not changed by baclofen (1.25-2.5 mg/kg) in either control or in 
ethanol-withdrawn rats. At a high dose (5 mg/kg) baclofen reduced 
the total number of arm entries in the plus-maze (Figure 3). 
Low doses of baclofen did not affect orienting response and 
locomotion in holeboard of both control and ethanol-withdrawn 
animals (Table 1) and a high dose (5 mg/kg) significantly reduced 
these measures (Table 1). Ethanol-withdrawn rats were more sen­
sitive than control to the inhibitory effect of high dose of baclofen 
(5 mg/kg) on locomotor activity in the holeboard test (Table 1). 
Analysis of covariance revealed that reduction of time spent in so­
cial interaction after 5 mg/kg of baclofen was dependent on the 
reduction in locomotor activity [F(l,12)=40.0, P<0.001]. 
Baclofen also suppressed tremor in ethanol-withdrawn rats. This 
effect was dose-dependent with maximum effect at 5.0 mg/kg (Figure 
4). 
Experiment 2. Effect of nitrendipine. As in the experiment 1, 
withdrawal from ethanol treatment resulted in a significant decrease 
of time spent in social interaction [F(l,8)=10.9, P<0.01]. However, 
the scores obtained in the social interaction test in experiment 2, 
were lower for both control and ethanol-withdrawn groups than 
in experiment 1 (Figure 1 and Table 2). The reason for these 
differences in scores of two experiments is unclear, however it might 
be proposed that these differences in scores were due to the repeated 
testing. The tremor scores for the groups withdrawn from ethanol 
did not significantly differ in experiment 1 and 2. Nitrendipine (25-
50 mg/kg) did not significantly affect the time spent in active social 
interaction (Table 2) or % number of entries into and the % time 
spent on the open arms of plus-maze (Table 3) of either control or 
ethanol-withdrawn rats. A high dose (100 mg/kg) of nitrendipine 
produced inhibition of the time spent in social interaction and a 
decrease of locomotor activity in social interaction test in both 
control and ethanol-withdrawn rats (Table 2). Analysis of covariance 
revealed that inhibition of social interaction by nitrendipine (100 
mg/kg) was due to the decrease in locomotor activity [F(l,8)=7.8, 
PCO.095]. Similarly, nitrendipine at the dose of 100 mg/kg reduced 
% number and % time spent on the open arms of plus-maze which 
was accompanied by a decrease in total number of entries (Table 3). 
At doses of 25-50 mg/kg nitrendipine did not affect tremor scores 
in ethanol-withdrawn rats, but the dose of 100 mg/kg significantly 
inhibited tremor (Figure 4). 
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Table 2 
Effect of nitrendipine on the time spent 
in active social interaction and the locomotor 
activity in social interaction test 
of control (CON) and ethanol withdrawn (EW) rats. 
The data are mean value ± SEM 
Drug dose 
(mg/kg) 
Time spent 
in social 
interaction (sec) 
CON EW 
locomotions 
CON EW 
Vehicle 100+9 47+13 75+11 46+10* 
Nitrendipine 25 86+23 32+9 66+20 48+6 
50 79+28 67+10 59+27 37+6 
100 37+14* 32+5 26+16* 12+3 ** 
+ - P<0.05 as compared to chronic control (CON). * - P<0.05; ** - P<0.01 
as compared to vehicle, n = 4-5 pair of rats per group. 
Table 3 
Mean (±S.E.M.) percentage of number of entries 
into open arms, percentage of time or open arms and 
total number of entries into the open and 
closed arms of the plus-maze by control and 
ethanol-withdrawn (EW) rats 30 min after 
administration of nitrendipine 
Group Dose % Number % Time Total 
(mg/kg) Number 
Control: vehicle 20.4+5.2 21.2+6.4 12.4+1.5 
Nitrendipine 25 20.4+5.1 18.1+6.1 8.7+1.9 
50 15.7+4.8 12.2+3.4 9.8+2.2 
100 13.1+4.7 4.4+1.5* 4.3+0.9* 
EW: vehicle 15.1+3.9 8,9+2.6+ 10.5+0.9 
Nitrendipine 25 16.1+3.9 7.5+1.0 6.5+0.7 
50 9.0+4.4 4.6+1.2 4.6+0.9 
100 6.6+2.6* 3.3+1.8* 3.8+0.8** 
n = 8-12 per group. + - P<0.05 as compared to control group; * - P<0.05; 
** - P<0.01 as compared to vehicle group. 
DISCUSSION 
In agreement with our previous study [12] withdrawal from 
chronic ethanol treatment produced in rats a strong anxiogenic re­
sponse, which could be detected in both tests of anxiety: social 
interaction test and plus-maze. The anxiogenic response was accom­
panied by the increased aggression and tremor, reflecting the state of 
withdrawal [21]. The data obtained in the present study show that 
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baclofen suppresses the anxiogenic response in ethanol-withdrawn 
rats. This effect of baclofen was only evident at the low doses 1.25-2.5 
mg/kg. A higher dose of baclofen (5 mg/kg) produced a nonspecific 
reduction of all behaviours recorded in both control and ethanol-
withdrawn groups. This is likely to reflect the sedative properties 
of this dose of baclofen [17]. Baclofen produced dose-dependent 
inhibition of aggression and tremor. This effect of baclofen could 
be observed not only at a high dose when it produced sedation but 
at the doses which did not induce sedative effect. On the basis of 
these data it might be proposed that baclofen given in relatively low 
doses at the withdrawal stage might reverse the anxiogenic response, 
aggression and tremor. 
In contrast, the dihydropyridine calcium channel antagonist ni­
trendipine, failed to affect anxiogenic withdrawal responses. Only 
at a high dose of 100 mg/kg nitrendipine did produce an inhibition 
of social interaction which was associated with inhibition of loco­
motor activity and tremor in both: control and ethanol-withdrawn 
rats. These data confirmed the previously obtained data [12] and 
suggested that inhibitory effect of nitrendipine on the tremor in 
ethanol-withdrawn rats might be due to the sedative action of this 
dose of nitrendipine. In this study as well as in the others nitrendip­
ine was used at the relatively high doses which obviously would have 
several peripheral effects, and therefore could not be employed for 
the treatment of abstinence signs in humans. 
The mechanism of action of baclofen on the signs of ethanol 
withdrawal is not clear. Although there is no direct evidence indi­
cating an involvement of GABAg receptor in the development of 
ethanol withdrawal syndrome one might propose that baclofen ex­
erts this effect via САВАд receptors in the CNS. САВАд receptors 
are broadly distributed within CNS and involved in the regulation 
of GABA, 5-hydroxytryptamine and noradrenaline release [2, 17]. 
Previous studies have shown that activation of САВАд receptors re­
duced the inward calcium current [7, 8] and enhanced slow outward 
potassium current in dorsal root ganglion [7]. Baclofen also inhibits 
the rise of synaptosomal free calcium in rat brain synaptosomes with 
an IC50 in the low micromolar range [24]. The reduction of voltage-
dependent calcium conductance and a decrease of [Ca2+]j in the 
nerve endings is most likely involved in the inhibition of amine re­
lease after administration of baclofen [2,15,17]. An increase in Ca2+ 
sensitivity in the nerve terminals is associated with increased amine 
release as a result of chronic ethanol treatment [20]. Previous studies 
have demonstrated the importance of GABA-benzodiazepine recep­
tor complex and 5-hydroxytryptamine in the regulation of anxiety [9]. 
It is possible that imbalance between these neurotransmitter systems 
is involved in the development of ethanol withdrawal anxiety also. 
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It might be proposed that baclofen, inhibiting calcium sensitivity 
and amine release, enhanced in ethanol-withdrawn rats, and thereby 
restores the balance between GABA and 5-hydroxytryptamine neu­
rotransmitter, systems and ameliorates signs of withdrawal. Recent 
studies have demonstrated an increase in the density of dihydropyri-
dine binding sites after chronic ethanol treatment [5, 22]. But unlike 
baclofen, dihydropyridines have little if any effect on synaptosomal 
calcium uptake and are not involved in the regulation of amine 
release [4]. Also it is not excluded that baclofen and dihydropy­
ridines affect different types of voltage sensitive calcium channels, 
which, might explain the difference in the effects of these drugs on 
the ethanol withdrawal signs. 
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Eats were treated for three weeks, twice daily, with periph­
eral benzodiazepine (PBD) receptor ligands Ro 5-4864 and PK 
11195 (both 10 mg/kg, i.p.). After the first injection there were 
no differences between the drug-treated and control animals in 
behavioral tests. After 10 days treatment, the number of sniffings 
was increased in Ro 5-4864 treated rats. After the last injection, 
sniffings and ambulations were decreased in PK 11195 treated ani­
mals. The number of reaiings and groomings remained unchanged 
throughout the treatment, and there were no changes in the re­
sults from elevated plus-maze test. Apparently these compounds 
are devoid of anxiolytic and anxiogenic effects at moderate doses. 
The effect of 72 h withdrawal from the above mentioned chronic 
treatment on PBD, central benzodiazepine (CBD), and GABA re­
ceptors was studied with receptor binding techniques using 3H-Ro 
5-4864, 3H-flumazenil and 3H-muscimol, respectively, as ligands. 
The number of GABA and CBD receptors was lower after Ro 
5-4864 treatment, as was the effect of progesterone-induced stim­
ulation of 3H-muscimol binding. However, the GABA stimulated 
3H-flunitrazepam binding remained unchanged after withdrawal 
from both, Ro 5-4864 and PK 11195. The number of PBD recep­
tors was decreased after Ro 5-4864 and PK 11195 treatments in 
olfactory bulb but not in cerebral cortex. The chronic treatment 
with PBD ligands Ro 5-4864 and PK 11195 produces different ef­
fects. Ro 5-4864, often presented as an agonist of PBD receptors, 
is behaviorally inactive. It affects, however, GABA/BD receptor 
complex linked to steroid binding fcites. PK 11195, often consid­
ered to be an antagonist, develops sedative action during chronic 
treatment, but withdrawal from it does not produce changes in 
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GABA/BD receptoi complex. 
KEY WORDS: Ro 5-4864; PK 11195; chronic treatment; behav­
ior; GABA and benzodiazepine receptois 
INTRODUCTION 
The existence of at least two different types of benzodiazepine 
(BD) receptors has been well documented. The central type BD 
receptors are present in the CNS [16] and a close correlation between 
the clinical potencies of BDs and their affinities for these binding sites 
indicates that they mediate the therapeutic actions of these drugs 
[25]. The peripheral type BD receptors are present both in peripheral 
tissues (adrenals, testis, kidney, heart, liver, spleen etc.) and CNS 
[for review see 22]. In spite of numerous studies, relatively little is 
known about the regulation and physiological role of the peripheral 
BD receptors. 4'-chlorodiazepam (Ro 5-4864) and the isoquinoline 
carboxamide, PK 11195 bind with high affinities to peripheral, but 
not to central BD receptors [15]. Ro 5-4864 induces convulsions and 
anxiety in rodents [6], displaces 35S-TBPS from picrotoxinin binding 
sites [27] and antagonizes the depolarizing eifect of muscimol on rat 
cuneate nucleus slices [23]. 
PK 11195 is known to antagonize some, but not all, of the effects 
of Ro 5-4864 [22]. Thus, Ro 5-4864 and PK 11195, are considered 
to be an agonist and antagonist of peripheral BD binding sites 
respectively. 
The effects of chronic treatment with central BD ligands have 
been extensively studied. However, very little is known about the 
effects of chronic treatment with specific peripheral BD receptor lig­
ands on behavior as well as on GABA and benzodiazepine receptors. 
Only recently it has been reported that two weeks treatment with 
PK 11195 reduces anxiety in humans [1]. 
The aim of the current study was to examine comparatively 
the effect of three weeks treatment with Ro 5-4864 and PK 11195, 
proposed agonist and antagonist of peripheral BD receptors, on 
behavior. Paiallely the effect of withdrawal from chronic treatment 
on GABA and both types of BD receptors in the rat brain was 
studied. 
METHODS 
Animals and drugs. Male Kuo:Wistar rats (National Laboratory 
Animal Center, Kuopio, Finland, 220-250 g) were housed five ani­
mals per cage in a room with a lighting cycle 20.00 - 07.00 dark peri­
od and allowed free access to food and water. 4'-chlorodiazepam (Ro 
5-4864, Fluka AG, Basle, Switzerland) and l-(2-chlorophenyl)-N-
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methyl-N-(l-methylpropyl)-3-isoquinoline carboxamide (PIC 11195. 
Pharmuka Laboratories, Gennevilliers, France) were dissolved in 
salme with a drop of Tween-80. The drugs were injected twice a day 
(at 9.00 and 20.00) intraperitoneal^ 60 and 120 min before open 
field and elevated plus-maze respectively, in concentrations to give 
an injection volume of 5 ml/kg and dose 10 mg/kg. Saline containing 
the same amount of Tween-S0 was used for control animals. The 
behavioral testings were carried out after the first daily injection. 
Apparatuses and registration procedure. A white circular test 
arena (diameter 83 cm, divided into 19 equal areas, walls 40 cm) 
with 65 lux light was used for open-field. On the test day, the rats 
were transferred into the laboratory in the morning and allowed to 
habituate for at least 30 mm. The behavior of rats was observed for 
5 min directly by an experienced experimentator. The number of 
rearings, sniffings, self-groomings, ambulations (stepping across the 
lines on the floor) and the time of non-mobile exploration (rats sniffed 
and looked around while remaining in one place) were registered. 
The animals were tested in an open-field after the first injection on 
1st, 11th and 21st day of treatment. 
The elevated plus-maze method described by Pellow and File 
[17]. In brief, the plus-maze consisted of two open arms, 50 x 10, 
and two enclosed arms, 50 x 10 x 25, with an open roof, arranged 
so that the two arms of the same kind were opposite to each other. 
The central compartment of the plus-maze was an open square, 10 
x 10 cm. During a 4-min test period the following observations were 
made: (a) number of open arm entries, (b) time spent in open and 
closed arms and, (c) total number of all arm entries. To begin the 
experiments, the animals were placed at the center of the plus-maze. 
The exploratory activity of rats treated with Ro 5-4864 and PK 
11195 was studied in an elevated plus-maze on 2nd and 22nd day 
(after morning injection) of chronic treatment with these drugs. 
The data of behavioral studies were manually transferred to 
a computer for automatic data handling (program by PC Soft Co, 
Joensuu, Finland). 
In vitro binding studies. 3H-flumazenil (Ro 15-1788, spec. act. 
79 Ci/mmol, New England Nuclear, Boston, MA), 3H-muscimol 
(spec. act. 22 Ci/mmol), 3H-flunitrazepam (spec. act. 81 Ci/mmol, 
both Amersham Radiochemicals, England) and 3H-Ro 5-4864 (spec, 
act. 89 Ci/mmol, New England Nuclear, Boston, MA) binding was 
carried out as described earlier [20,21]. Steroid hormone stimulat­
ed 3H-muscimol binding was carried out as described by Lõpez-
Colomõ et ai. [13] with minor modifications. The tissues were 
homogenized in 30 vol. 25 mM K2HPO4/KH2PO4 containing 50 
mM KCl (pH 7.4) with Ultraturrax homogenizer (5 s, setting 6) and 
washed twice in the same buffer by centrifugation (48,000 x g for 20 
66 
min). The final pellets were stored overnight at - 20° C. After thaw­
ing they were rehomogenized and washed additionally four times 
in the same buffer for basal and steroid stimulated 3H-muscimol 
binding. The reaction was initiated by the addition of tissue and 
terminated after incubation (30 min on ice) by rapid filtration over 
Whatman GF/B filters. 
GABA (Sigma, St. Louis, MO), flunitrazepam (Hoffmann La-
Roche, Basle, Switzerland) and PK 11195 (Pharmuka Laboratories, 
Gennevilliers, France) were used to determine the specific binding to 
GABA, central- and peripheral BD receptors respectively. Proges­
terone, 4-androstene-3,17-dione (androstenedione) and GABA (all 
from Sigma, St. Louis, MO) were used to stimulate 3H-muscimol 
binding. Specific binding was calculated by subtracting the nonspe­
cific from total binding. Protein content was measured by the Lowry 
et al. [14] method. 
Calculations and statistics. Maximum binding (Bmaa) and affin­
ity constants (KD) were calculated using Scatchard analysis. The 
Scatchard plots were computed with the curve-fitting program Enzfit-
ter. The significance of the differences between the binding data was 
calculated using two-tailed Student's t-test. The differences between 
control and treated animals in open-field and elevated plus-maze 
were assessed by Mann-Whitney U-test and ANOVA respectively. P 
< 0.05 was considered statistically different. 
RESULTS 
The effect of acute and chronical treatment with Ro 5-4864 and 
PK 11196 on behavior of rats in open-field. The acute treatment (first 
day, first injection) of rats with Ro 5-4864 (10 mg/kg) and PIC 11195 
(10 mg/kg) did not change any of the behavioral parameters studied 
in the open-field (Fig. 1,2). Treatment during 10 days (10 mg/kg, 
twice a day, behavior tested after 1st injection on 11th day) with 
Ro 5-4864 significantly increased the number of sniffings (Fig.l) but 
had only a slight tendency to increase rearings (data not shown) and 
ambulations (Fig.2). After 10 days of administration PIC 11195 (10 
mg/kg, twice a day) did not have any statistically significant effects 
on behavior (Fig. 1,2). However, after 20 days treatment (10 mg/kg, 
twice a day, behavior tested after 1st injection on 21st day) PK 11195 
significantly reduced the number of sniffings and ambulations (Fig. 
1,2). Ro 5-4864 lacked this effect of PIC 11195, i.e. after 20 days of 
treatment it did not change either the number of rearings (data not 
shown) or sniffings or grooming (Fig. 1,2). 
The effect of acute and chronic treatment with Ro 5-4864 and 
PK 11195 on exploratory activity of rats in an elevated plus-maze. 
Treatment with neither Ro 5-4864 nor PIC 11195 caused any signifi-
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Figure 1. The effect of chronical treatment with Ro 5-4864 (10 mg/kg) 
and PK 11195 (10 mg/kg) on the number of sniffings in open field. The drugs 
were administered twice a day. The behavioral experiments were carried 
out after morning injection. The data presented are mean ± S.E.M. of 10 
animals per group. * - P < 0.05 as compared to saline treated controls. 
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Figure 2. The effect of chronical treatment with Ro 5-4864 (10 mg/kg) 
and PK 11195 (10 mg/kg) on the number of ambulations in open field. 
The drugs were administered twice a day. The behavioral experiments were 
carried out after morning injection. The data presented are mean ± S.E.M. 
of 10 animals per group. * - P < 0.05 as compared to saline treated controls. 
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cant changes of the behavioral parameters registered in an elevated 
plus-maze. Hovever, in the beginning of the treatment only Ro 5-
4864 had a tendency to decrease the proportion of time spent in the 
open arms. After the last injection (on 22nd day) the reverse was 
observed i.e. only PK 11195 seemed to lower the amount of time 
spent in open arms (Fig.3). 
Day 2 Day 22 
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Figure 3. The effect of chronical treatment with Ro 5-4864 (10 mg/kg) 
and PK 11195 (10 mg/kg) on the % of time spent in the elevated plus-maze 
open aims. The drugs were administered twice a day. The behavioral 
experiments were carried out after morning injection. The data presented 
are mean ± S.E.M. of 10 яштя.к per group. 
The effect of withdrawal from chronic treatment with Ro 5-4864 
and PK 11195 on central — and peripheral BD receptors. Chronic 
treatment with PIC 11195 and Ro 5-4864 lowered the number of 3H-
Ro 5-4864 binding in olfactory bulb but not in cerebral cortex (Table 
1). Only Ro 5-4864 lowered the the density of central BD receptors 
labeled by 3H-flumazenil in cerebral cortex (Table 2). Chronic 
treatment with both of the peripheral benzodiazepine ligands did 
not change the affinity constants of neither 3H-Ro 5-4864 nor 3H-
flumazenil (Tables 1,2). 
The effect of withdrawal from chronic treatment with Ro 5-
4864 and PK 11195 on 3H-musciniol and GABA - stimulated 3H-
flunitrazepam. Chronic treatment with PIC 11195 did not change 
either basal or progesterone and androstenedione stimulated 3H-
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Table 1 
The effect of withdrawal (72 h) from chronic 
treatment with Ro 5-4864 and PK 11195 on 3H-Ro 5-4864 
binding in the rat cerebral cortex and olfactory bulb. 
The data presented are mean ± S.E.M. of 3-5 determinations 
each carried out in triplicate. Statistical comparisons 
were made using two-tailed Students t-test 
Treatment, 
mg/kg twice 
a day 
3H-Ro 5-4864 
Bmax (fmol/mg) K D  (nM) 
Saline 
Ro 5-4864 10 
PK 11195 10 
Saline 
Ro 5-4864 
PK 11195 
Cerebral cortex 
304 ± 56 3.67 ± 0.87 
446 ± 69 5.47 ± 1.08 
177 ± 36 2.32 ± 0.71 
Olfactory bulb 
1672 ± 91 2.41 ± 0.25 
843 ± 81* 1.91 ± 0.28 
897 ± 86* 2.18 ± 0.41 
* - P < 0.01 as compared to saline controls 
Table 2 
The effect of withdrawal (72 h) from chronic 
treatment with Ro 5-4864 and PK 11195 on 3H-flumazenil 
and 3H-muscimol binding in the rat cerebral cortex. 
The data presented are mean ± S.E.M. of 3-5 determinations 
carried out in triplicate. Statistical comparisons were made 
using two-tailed Students t-test 
Treatment, 
mg/kg twice 
a day 
Binding characteristics 
Emas (fmol/mg) KD (nM) 
3H-flumazenil 
Saline 2151 ± 59 1.97 ± 0.30 
Ro 5-4864 10 1782 ± 50* 1.81 ± 0.13 
PK 11195 10 1896 ± 66 2.02 ± 0.18 
3H-muscimol 
Saline 2530 ± 98 23.61 ± 1.82 
Ro 5-4864 10 1823 ± 93* 17.12 ± 2.60 
PK 11195 10 2305 ± 291 29.55 ± 3.55 
* - P < 0.05 as compared to saline treated controls 
muscimol binding characteristics (Table 2, Fig.4). Ro 5-4864 treat­
ment lowered significantly the number of 3H-muscimol binding sites 
in cerebral cortex (Table 2) and decreased the stimulation of 3H-
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muscimol binding caused by steroids (Fig.4). Chronic treatment with 
neither Ro 5-4864 nor PK 11195 changed the GABA stimulated 
3 H-flunitrazepam binding in cerebral cortex (Fig.5). 
DISCUSSION 
Ro 5-4864, a proposed agonist of peripheral BD receptors, has 
anxiogenic effects that are not reversed by the suggested antagonist 
of these receptors, PK 11195 [7,8]. Interestingly, PIC 11195 itself 
has also anxiogenic activity [8]. Additionally to anxiogenic effects 
Ro 5-4864 can cause convulsions that are reversed by PK 11195 
pretreatment [5]. However, all the behavioral effects of peripheral 
BD ligands reported appear in the doses far higher (20-60 mg/kg 
and 30-90 mg/kg for Ro 5-4864 and PK 11195 respectively) than 
those needed to saturate these receptors [8,19]. Therefore, we decided 
to carry out a chronic treatment with a more moderate dose of Ro 5-
4864 and PK 11195 (10 mg/kg) to examine comparatively the effects 
of acute and repeated treatment on behavior. 
After the first treatment both of the drugs studied were without 
any significant behavioral effects in the open field test. After 10 
days treatment with Ro 5-4864 only the number of sniffings was 
significantly increased. The number of ambulations also had a 
tendency to be increased after Ro 5-4864 treatment. However, after 
20 days treatment these changes were not present any more. After 21 
days of treatment, Ro 5-4864 had a tendency to increase the amount 
of time spent in the open arms of the elevated plus-maze. This may 
indirectly support the earlier observation of Zbinden and Randall 
[28] that Ro 5-4864 has a tranquilizing effect in humans. However, 
most probably the moderate behavioral effects of Ro 5-4864 observed 
in our studies reflect increased arousal. Electrophysiological studies 
indicate that Ro 5-4864 has both in vitro and in vivo effects opposite 
to those of the benzodiazepine tranquilizers [18,26]. 
In contrast to Ro 5-4864, chronic treatment with PIC 11195 
during 20 days resulted in a significant decrease of the number 
of sniffings and ambulations. The proportion of time spent in 
the open arms of the elevated plus-maze was also considerably 
(although not significantly) less than in controls. The development 
of these behavioral effects after chronic treatment with PK 11195 
is difficult to explain. So far, it has only been demonstrated that 
no tolerance develops to anticonvulsant action of PIC 11195 (agahist 
Ro 5-4864 induced convulsions) but rapid tolerance develops to 
its proconvulsant effect [5]. The behavioral actions of PK 11195 
that develop during chronic treatment resemble either sedative or 
anxiogenic effects. In acute experiments no sedative action of PIC 
11195 has been reported. However, only a very high dose of PK 
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Figure 4. The effect of chronical treatment with Ro 5-4864 (10 mg/kg, 
twice a day) and PK 11195 (10 mg/kg, twice a day) on progesterone (30 
//M) and androstenedione (30 дМ) stimulated 3H-muscimol binding in the 
rat cerebral cortex after j2 h of withdrawal. The data represent mean i 
S.E.M. of 3-5 determinations each carried out in triplicate. * — P < 0.05 as 
compared to saline treated animals. 
1 6 0  
10 1 0.1 0.06 
I I Sal 11! PK Е2Э Ro 
Figure 5. The effect of chronic treatment with Ro 5-4864 (10 mg/kg, 
twice a day), and PK 11195 (10 mg/kg, twice a day) on GABA (10 /iM) 
stimulated 3H-flunitrazepam binding in rat cerebral cortex afier 72 h of 
withdrawal. The data represent mean ± S.E.M. of 3 determinations each 
carried out in triplicate. 
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11195 (90 mg/kg) reduces social interaction indicating a possible 
anxiogenic effect [8]. 
Withdrawal from chronic treatment with Ro 5-4864 resulted 
in a decreased number of GABA and central BD receptors in the 
rat cerebral cortex. In contrast, PK 11195 treatment did not cause 
any significant changes of these receptors. The findings with Ro 
5-4864 seem to be in line with the recent data demonstrating that 
Ro 5-4864 is coupled functionally to a GABA-regulated chloride 
ionophore labeled by the cage convulsant 35S-TBPS [9,10]. It has 
also been proposed that GABA/benzodiazepine receptor complex 
linked to a Ro 5-4864 binding site is allosterically coupled to the 
putative steroid recognition site [3]. 
Recently Lõpez-Colomõ et ai. [13] demonstrated the enhance­
ment of 3H-muscimol binding to brain synaptic membranes by 
progesterone and related pregnanes. In our study, withdrawal 
from Ro 5-4864, but not PK 11195, lowered the stimulation of 
3H-muscimol binding by progesterone and androstenedione. The 
two prototypic peripheral BD ligands, Ro 5-4864 and PK 11195, 
may not label identical populations of binding sites. Sites la­
beled by these two ligands have been shown to be differentially 
influenced by several agents, including arachidonate [24], detergents 
such as Triton X-100, 3-[(3-cholamidopropyl)dimethylainmonio]-l-
propanesulfonate (CHAPS), and Tween 20 [3], and by chemical 
modification by phospholipase A2 [11]. Nevertheless, in our studies 
both Ro 5-4864 and PK 11195, caused similar downregulation of 
3H-Ro 5-4864 binding in olfactory bulb but not in cerebral cortex. 
After withdrawal from chronic treatment with agonist and an­
tagonist one would expect different, rather than similar effects on 
the common receptor for these ligands. Similar effects may evidence 
that both these ligands can share agonistic properties. Indeed, in 
several studies it has been shown that PK 11195 can not antagonize 
all the effects of Ro 5-4864 [4,26] and in some cases can even mimic 
the effects of Ro 5-4864 [4,12]. The data obtained give evidence that 
even relatively high doses (10 mg/kg) of peripheral benzodiazepine 
ligands, both after single or chronical tratment, have very few, if any 
behavioral effects. However, chronic treatment with PK 11195 seems 
to cause mild sedation. Thus, if any therapeutic applications can be 
found for peripheral BD receptor ligands, these compounds would be 
without major unwanted behavioral side effects even during chronic 
treatment. 
In conclusion, Ro 5-4864 and PK 11195, proposed agonist and 
antagonist of peripheral BD receptors respectively, have moderate 
but still different effects on behavior during chronic treatment. The 
chronic treatment with the peripheral BD ligands also affects GABA 
and central BD receptors differently but affects similarly peripheral 
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BD receptors in CNS. 
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THE SIGNIFICANT ROLE OF LOCAL 
CONFORMATIONAL CHANGES 
IN FUNCTIONING OF TRANSMEMBRANE 
PROTEINS (Na, K-ATPase) 
M. Zilmer, T. Kullisaar. K. Zilmer, 
T. Vihalemm, R. Kask, L. Tähepõld 
Department of Biochemistry and Laboratory of Enzymology 
of Tartu University 
This article develops our earlier conception [10, 14, 16], 
which suggest that the changes (domenic changes) in conformation 
of transmembrane proteins (Na, K-ATPase) play a crucial role in 
the functioning of these proteins. It means, that the realization of 
some functions of these proteins is quaranteed already by local of 
changes (alteration) of their conformation. On the occasion of Na-
pump such kind changes underlay on regulation of functioning 
of Na, K-AUW with several effectors, of the fulfillment of 
partial reactions etc. Although we analyze this conception by 
investigation of Na-pump, it seems that such conception is valid 
for several membrane proteins, including receptors. 
KEY-WORDS: Narpump; lipid-protein interactions; conforma­
tions; brain tumors 
INTRODUCTION 
Na-pump is an integral plasmatic membrane protein, which 
protomer consists af o- and /3-subunits [18]. With molecular cloning 
of cDNAs the complete amino acid sequences of these subunits 
(SU) from several species has been detected [3, 17]. Na-pump is 
characterized by cooperative interactions with Na+ and К^ [6, 13] 
and membrane lipids are engaged in the regulation of the functions 
of the Na, K-ATPase [2, 20, 21]. Under the pathological states the 
activity and some of the properties of Na-pump undergo alterations 
[4, 16, 22]. 
It is known, that the major subunit of Na, K-ATPase (o-SU) 
has 7-8 membrane-segments, very little extracellular structure, and 
two large cytoplasmatic domains [8]. The first is located near the 
amino terminus (Fig. 1) and may be promote the exchange, the 
second region evidently mediates phosphorylation, ATP binding, 
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and, probably the ATPase activity. The single extracellular loop is 
connected with ouabain binding. The /З-SU (the smaller SU) consists 
of a single membrane spanning segment [3, 8], a short cytoplasmic 
domain, and relatively large extracellular sequence (Fig. 1). The last 
part contains some glycosylation sites. 
Figure 1. Localization of Na, K-ATPase snbnnita according to Brown 
et aL [ ] Jorgeneon [ ]. 
Although valuable information of the structure of the Na-pump 
has been collected, nevertheless there is not a great deal known about 
the relations between the changes of conformation and functions of 
this pump. The decoding of these relations, no doubt, is very impor­
tant and it considerably' enlarges our knowledge about functioning 
of other transmembrane proteins (e.g. receptors) on the whole. In 
this article we analyze data which prove our earlier suggestion [10, 
11, 14, 16] that the local changes of conformation (LCC) play the 
primary role in the functioning of the Na-pump of the brain. It 
means, that the fulfillment of some processes is completely realized 
by of the LCC of Na, K-ATPase system. 
The enzyme preparations (EP) of Na, K-ATPase from nor­
mal brain tissue of adult Wistar rat (NBT), of young (7-11 days) 
Wistar rats (YE), of human normal brain tissue (HNBT) and of hu­
man tumorous brain tissue (HTBT) were isolated according to our 
method of Karelson et a! [9]. The Hill's coefficients (n#), treatment 
with desensibilizators and inhibition of enzyme with pCMB and 
MCCD were performed as described earlier [15, 16, 24]. The floures-
cence measurements (quenching of tryptophan fluorescence) were 
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made according to the procedure of Tyson and Sternberg [19], using 
Perkin-Elmer spectroflourometer LS-5. Fluorescence quenching was 
analyzed after to the modified Stern-Volmer eguation and values of 
f0 and K„ (the fractional accessible flourescence and the quenching 
constant, respectively) were calculated [12, 19]. The temperature 
inactivation of Na-pump was studied range in 45-52o С anf К у 
(the constant of termoinactivation rate) and sS (change of entropy) 
were calculated [7]. The hormone binding ability (HBA) of subunits 
of Na, K-ATPase was determined then in presence or absene of ATP 
(5mM), NaCl (lOOmM), and MgCl2 (4mM), and phosphatidylinosi-
tol (30 M) by radioimmunoaassay (RIA) method using commercial 
kits (CEA-IRE-SOMN for ACTH, PROL; The Bioorganic Institute 
of the BSSR for CORT). The HBA was expressed as a percentage 
of total activity of the labelled hormone. Attempting to avoid un-
specific binding several control-tests were used, The subunits of Na, 
K-ATPase were separated by PAGE-system and after removing from 
slices of gels were concentrated by ultrafiltration (Diaflo Ultrafilters 
ТУре YM-10). The protein content was determined by the modified 
method of Lowry et al. [1] and the specific activity of Na, K-ATPase 
was expressed in уяпо! Р,- per mg protein per minute. 
RESULTS AND DISCUSSION 
Our previous studies [10, 14, 15, 16] demonstrated that in case 
of Na-pump from NBT (or HNBT) on the Arrhenius plot the typi­
cal break at 20-22oC appeared and that njj for Na"*" and K""" were 
1,7-1,8 and 1,4, respectively. On the occasion of EP from HTBT, this 
break was not revealed at 20-22oC, but appeared at 27,5-30,5oC. 
At the same time the nц for Na+ with Na-pump from HTBT was 
only 0.9, but cooperative binding of K+ was preserved (n# = 1.3). 
On the basis of these data we can suggest, that the break at 27.5-
30.5oC is, probably, associated with LCC of protein component of 
Na-pump. Our suggestion has been supported by the temperature 
dependence experiments which show that the nonlinearity of Arrhe­
nius plot above 20oC is delipidation-independent and therefore is not 
conditioned by alterations of the membrane itself, but is. associated 
with confo mational changes of enzyme protein [5]. 
A further evidence for the role of LCC in Na-pump is also 
obtained by the experiments with blocators of functional groups 
of Na-pump. In Table 1, it is shown that the protective effects of 
ATP against the both blocators is depending on testtemperature. 
A more remarkable temperature-dependent difference the protective 
effect of ATP was noticed in case of blocator SH-groups (pCMB) 
and especially clear difference was detected between EP fromm NBT 
and HTBT at both 37oC and 28-29,5oC (Table 1.). Obviously, the 
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temperature interval from 27,5o to 30,5oC is associated with the 
certain alterations in the LCC of Na-pump, which leads to some 
changes in the SH-groups packing. This assumption is supported 
by the detection of the break on Arrhenius plot in case of NBT 
at 27.5-30.5oC after treatment EP with agents which cause most 
significant alterations in the SH-groups packing [15, 16]. 
Table 1 
Protective effects of ATP (5mM) against 1,4-1,5 ßM pCMB 
and 1,0-2,0 mM MCCD (data for MCCD are represented 
in the parenthesis) 
Temperature 37oC 28-29,5oC 
Enzyme NBT HTBT NBT HTBT 
preparations 
-
Inhibition of 44±2,0 49±3,5 52±4,0 60±9 
Na, K-ATPase, % (52±8,3) (42±7,3)* (48±7,3) *(49±5,6)* 
Protective effect 92±4,0 21±4,1 60±5,8 No detectable 
of ATP, % (50±7,3)* (25±6,0)* (65±4,8)* (10±3)* 
* The results are expressed as M±SEM (n = 5-6); the preincubation was 
10 and 75 min. for pCMB and MCCD, respectively. 
Proceeding йот above-mentioned conception we investigated 
also the cooperativity of Na+ and K+ to Na-pump at different tem­
peratures. We found, that n# at 37oC was 1,8±0,07 and 1,4±0,06 
and at 25.5-30.5oC 1,3±0,06 and 1,3±0,08 for Na+ and K+, respec­
tively. Therefore, the definite decrease of n# for Na+ (p<0.005 vs 
37oC), but not for K+ is in good agreement with the suggestion, 
that the cooperativity for Na+ (e.g. allosteric properties for Na+) 
eUminates more easily than the cooperativity for K+ [16, 20], while 
the maintenance cooperativity for K+ does not need interprotomeric 
interactions. That all, together, corroborated with LCC of Na-pump. 
It is known, that the differences in the thermodynamic pa­
rameters are conditioned by alterations of protein's conformations 
[7Q. Termoinactivation of Na-pump indicated, that Kj was 1.69 
and 1.29 at 52oC for enzymes from normal brain tissue and from 
tumorous brain tissue, respectively. At the same time, in case of 
NBT AS* was 59,8 cal/(mol*grade) and in case of HTBT AS* = 
113,1 cal/(mol*grade) at 55 oC. Consequently, these data reflect the 
conformational differences between Na-pump from NBT and HTBT 
and particularly, that the Na, K-ATPase in the tumorous brain tissue 
has more stable conformational state than in the normal brain tissue. 
This viewpoint is also supported by stability of the cooperativity for 
K+ [23]. 
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Our following experiments (quenching of tryptophan fioures-
cence) give the results, which aie in favour of the abovementioned 
comprehensions. As is shown in Table 2 the f0 and Ka for both 
NBT (without or with Na+) and for HTBT (without or with Na'1') 
have a remarkable difference, (it is particularly clearly revealed in 
the presence of Na+). At the same time the values of K0 in the 
presence of K+ in case of NBT and HTBT are not so different and 
K0 for both HTBT and HTBT+K+ are practically similar. 
T a b l e  2  
Quenching parameters of Na, K-ATPase determined from 
modified Stern-Volmer plots 
(FO/FQ-F versus [acrylamidejM-1) 
Temparature 28,5oC 
fa Ka 
NBT 0,92±0,020 4,3±0,49 
+ 20mM Na+ 0,70±0,034 9,4±0,65 
+ 10-20mM K+ 0,70±0,009 11,9±0,96 
HTBT 0,75+0,016 7,7±0,89 
+ 20mM Na+ 0,93±0,019 4,8±0,39 
10-20mM K+ 0,71±0,014 8,5±0,40 
* The results aze expressed as M±SEM (n = 3-4) 
It must be pointed out that especially clearly are LCC expressed 
in parameters of Na-pump, associated with Na+. This is in good 
agreement with our experiments, which demonstrated that the HBA 
for ACTH could be never detected in the case of protomer (aß) and 
subunits (a or ß) of Na, K-ATPase from HTBT. At the same time 
the HBA for ACTH in all experiments increased (10-30%) after the 
addition of Na+ in the presence of Mg2+, ATP, phospholipid in 
spite of sources (NBT, HNBT or YR) of protomer and subunits of 
Na-pump. 
On the basis of the above-mentioned facts and assumptions it 
should be concluded, that LCC (domenic conformational changes) 
of transmembrane brain Narpump play an important, perhaps, a 
crucial role in the regulation and functioning of this pump. 
In conclusion, attention should be called to some aspects in the 
respect the whole complex (protein + lipids + carbohydrates) of Na, 
K-ATPase: 
1) The data, presented in this article do not eliminate the impor­
tant role of the membrane lipids in the regulation of the functioning 
of brain Na, K-ATPase (see 21, 23); 2) The abovementioned data 
and our new, unpublished facts (ouabain-binding, interaction with 
peptides etc.) allow to suggest that in tumorous brain tissue the 
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Na-pump is, probably, in "K+-opportune conformation"; 3) The 
disturbance of the cooperativity for Na+ in EP from HTBT belongs 
to the group of phenomena which are connected with intensive 
growth of tumorous cell [23]. We suppose that the general basis 
of all these phenomena arises from the alterations of conformation 
(and localization) of oSU in the membrane. The latest, probably, 
remarkably  depends  on  changes  in  the  carbohydrate  chains  o f  ß-
Su (Figure 1). The investigation of this problem (e.g.) the role of 
carbohydrate chains in functioning of Narpump) is just in progress. 
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Several studies have shown elevated glycolysis in the various 
tumor cells, particularly in the cancer cells, and the increased role of 
glycolysis in the generating of cell ATP pool [see for example, 4]. The 
enhancement of the glycolysis is in accordance with the development 
of hypoxia and is accompanied with intensive production of H+. 
At the same time it is known that intracellular ratio of Na+ 
and K+ (Na,7K,-) is connected with transcription, i.e. the certain 
increase of Na, plays a definite role in the intensive growth of 
tumour cells [5]. Therefore, in case of the cancer cells the effective 
system for elimination of excess H+ with simultaneous creation of 
suitable Na,/I<j should exist. The aim of the present paper is to 
put forward a hypothesis how the co-operation of Na-pump and 
Na+/H+-exchange can resolve these problems. 
Numerous studies have reported that several factors (growth 
factors, oncoproteins) activate Na+/H+-exchange, evidently by in­
ositol lipids pathway [see for instance 3]. Although, the activation 
of Na+ / H+-exchange is accompanied with elevation of transport of 
H+ from cells, we suppose, that in case of very intensive release of 
H+ (see above) in the tumour cells an additional transport of H+ 
from cells should take place. This is the transport by Na-pump, 
i.e. the co-transport with Na+ (Fig. 1.) Our hypothesis could be 
grounded on the following circum-stances. The Na-pump works in 
the membrane of the tumour cell quite intensively due to abundance 
of glycolytical ATP. At the setme time the normal active transport 
of H+ is to a certain extend diminished whereas some properties 
of the Na-pump from the tumorous tissue are altered [7, 8, 10]. 
This diminishing is proba-bly an adaptation phenomenon in case 
of cancer (at least in case of glioma) whereas one part of H+ is 
transported by Na-pump. This co-operation between Na-pump and 
Na+ / H+-exchange in cancer cells resolve the problems which are 
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associated with intracellular pH and Na+/K+ (Fig. 1). Numerous 
facts are in accordance with our hypothesis: 1) The affinity for H+ 
to the Na-pump is considerably higher than the affinity for Na+ [9], 
2) in the acidic medium the /K+-exchange and ATPase activity 
also exist without Na+ [2], 3) The intracellular pH in case of cancer 
cells is, to a certain extend, lower than in the cells of normal tissue, 
4) Na+ can substitute H+ and vice versa as a coupling ion [7]. 
It is very likely , that they also substitute each other to a certain 
extend (in certain conditions) in case of Na-pump. The со-transport 
effectivity depends of [H+] and [Na+] in the cell, 5) At saturating 
cytoplasmic [Na+] the ratio of the Na+ transported per ATP in the 
acidic medium decreases to 1.5:1 [1], 6) The functionality of the 
Na-pump, i.e. the transition between the Na-from (a deprotonated 
from) and K-form (a protonated form) [6] is also in accordance with 
our hypothesis (see Fig. 1). 
(Н*Жа Na4 H* SIGNAL 
Synthesis of DNA, transcription, synthesis of several 
proteins 
Figure 1. Cooperation between Na-pump and Na/H-excange in case 
of caacei (IL - inositool lipids, R - receptor, С - protein kinase C, Signal -
growth factors, oncogenes) 
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